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ABSTRACT 
THE ROLE OF GLYCOGEN SYNTHASE KINASE 3 BETA IN 
INTERFERON BETA BIOLOGY 
Huizhi Wang 
April 16, 2009 
It has been shown that GSK3 ~ plays a critical role in the inflammation response 
by differentially regulating MyD88-dependent pro- and anti-inflammatory cytokines 
production in TLR4-stimulated innate immune cells. The work included in this 
dissertation demonstrates that (I) GSK3~ negatively regulates the production of the TLR4 
dependent and MyD88-independent cytokine, IFN ~, by controlling the levels of total c-
Jun and thereby modulating the amount of c-Jun / ATF2 complexes, and (II) that IFN ~ 
induces IL-l 0 in dendritic cells by regulating GSK3 ~ activity. 
Part I: TLR4 stimulation of macrophages has been shown to induce the 
production of interferon-B (IFN-B) via the MyD88-independent pathway. Here we 
demonstrate that glycogen synthase kinase 3-~ (GSK3-~) plays a fundamental role in this 
process. Suppression of GSK3-B activity by pharmacological inhibition, siRNA-mediated 
gene silencing, or ectopic expression of a kinase-dead GSK3-B mutant, augmented IFN-B 
production by TLR4-stimulated macrophages. Conversely, ectopic expression of a 
constitutively active GSK3-B mutant severely attenuated IFN-B production. GSK3-B was 
found to negatively control the cellular levels of the transcription factor c-Jun and its 
nuclear association with ATF-2. siRNA-mediated knockdown of c-Jun levels abrogated 
VI 
the ability of GSK3-~ inhibition to augment IFN-~ production by TLR4 stimulated 
macrophages. Inhibition of GSK3 in vivo resulted in potently augmenting the systemic 
levels of IFN-~ in mice that were administered LPS. These findings identified a novel 
regulatory pathway controlling IFN-~ production by TLR4-stimulated innate immune 
cells. 
Part II: IFN-~ is known to induce the production oflL-1 0 by innate immune cells, 
yet the underlying cellular mechanisms responsible for this effect are unknown. Here, we 
demonstrate that the constitutively active serine/threonine kinase, GSK3-f3, controls the 
IFN-~-mediated production oflL-1 0 by human dendritic cells. Stimulation of cells with 
IFN-f3 induced the activation of the phosphatidylinositol 3-kinase (PI3K) pathway and 
blockade of PI3K activity inhibited the ability of IFN-~ to induce IL-IO production. 
Assessment of downstream kinases within the PI3K pathway demonstrated that IFN-~ 
induced the phosphorylation and subsequent suppression of GSK3r) activity. Direct 
inhibition of GSK3 activity via pharmacological inhibition, siRNA-mediated knockdown 
of GSK3-f3, or ectopic expression of a kinase dead GSK3-f3 potently augmented the 
levels of IL-l 0 produced by type I IFN-stimulated dendritic cells, whereas no affect on 
the production of pro-inflammatory cytokines was observed. In contrast, ectopic 
expression of a constitutively active GSK3-f3 mutant severely attenuated the levels of IL-
10 produced by IFN-~-stimulated cells. Analysis of transcription factors involved in the 
regulation of IL-IO showed that IFN-f3 increased the nuclear levels of phospho-CREB 
and this effect was dependent upon the ability of IFN-f3 to induce PI3K activity and 
inactivate GSK3-~. These findings identify the cellular mechanism by which IFN-f3 
induces IL-l 0 production by innate immune cells. 
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The immune system of vertebrates consists of two broad components that comprise 
innate and adaptive immune immunity. The innate immune system is an ancient form of 
host defense and is conserved in all multicellular organisms (l). As the first line of 
defense against microbial pathogens, the innate immune system of mammals consists of 
surface barriers, humoral factors, macrophages, NK cells, and dendritic cells (Des) (2). 
Upon microbial invasion, distinct families of pattern-recognition receptors (PRRs) initiate 
intracellular signaling events that link the recognition of a pathogen to the nuclear 
transcription of host defense genes. The most widely studied and characterized PRRs 
include Toll-like receptors (TLRs) that recognize highly conserved molecular patterns 
derived from bacteria, viruses, protozoa and fungi (3). These receptors recruit adaptor 
molecules that create multi-protein platforms that then recruit and/or activate downstream 
kinases. These events, among others, lead to the engagement of several signaling 
pathways culminating in activation of nuclear transcription factor kappa B (NF-KB), 
mitogen-activated protein kinase (MAPK), and interferon regulatory factors (IRFs) that 
control the transcription of genes encoding inflammatory cytokines and type I interferon, 
which are important for eliminating invading pathogens. 
Toll was originally identified as receptor that is expressed by insects and was found 
to be essential for establishing dorsoventral polarity during embryogenesis (4). 
Subsequent studies revealed that Toll also played an essential role in the insect innate 
immune response against fungal infections (5). Homologues of Toll identified through 
database searches have identified at least 13 members ofTLRs (6). TLRI-9 are common 
to humans and mice. TLRI0 appears to be functional only in humans, whereas TLRII-13 
have been found in mouse and less characterized (7-9). Each TLR appears to recognize 
distinct PAMPs derived from various microorganisms including bacteria, viruses, 
protozoa and fungi. TLRs are classified as type I transmembrane proteins characterized 
by an ectodomain composed of leucine rich repeats (LRR) that are responsible for 
recognition of PAMPs and a cytoplasmic domain homologous to the cytoplasmic region 
of the IL-l receptor, known as the TIR domain, which is required for downstream 
signaling (10). TLRs are classified into several groups based on the types of PAMPs they 
recogmze. The first class contains TLRl, 2, 4 and 6 which recognize lipids. For 
example, TLR4, together with its extracellular components such as MD-2 and CDI4, 
recognizes lipopolysaccharide (LPS) from Gram-negative bacterial. TLR2 forms 
heterodimers with TLRI or TLR6, as well as non-TLRs such as CD36 to discriminate 
among a wide array of PAMPs, including peptidoglycan, lipopeptides and lipoproteins of 
Gram-positive bacteria, mycoplasma lipopeptides and fungal zymosan (11). In addition, 
human TLRI0 is thought to complex with TLR2 and TLRl, although a ligand for this 
complex remains unknown. The second class of TLRs contains TLR5 and TLR 11 and 
recognize protein ligands (12-14). TLR5 is expressed abundantly in intestinal CDllc-
positive lamina propria cells where it senses bacterial flagellin (15). Mouse TLR 11 
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recogmzes an unknown component(s) of uropathogenic bacterial, and a profilin-like 
molecule of the protozoan parasite Toxoplasma gondii (16, 17). The third class of TLRs 
includes TLR3, 7, 8 and 9, which are localized intracellularly where they detect nucleic 
acids derived from viruses and bacteria (18, 19). TLR3 was shown to recognize double 
stranded RNA (dsRNA), which is produced by many viruses during replication. TLR7 
recognizes synthetic imidazoquinoline-like molecules, guanosine analogs, single stranded 
RNA (ssRNA) derived from various viruses and small interfering RNA (20). Human 
TLR8 is similar to TLR7 in that it recognizes imidazoquinolines and ssRNA (20). 
However, the ligands of mouse TLR8 are unknown. TLR9 recognizes CpG DNA motifs 
present in bacterial and viral genomes as well as non-nucleic acids such as hemozoin 
from the malaria parasite (11). 
Lipopolysaccharide (LPS), a membrane glycolipid of Gram-negative bacteria, is a 
mediator of inflammation (21). The ability of the TLR4 complex to recognize LPS 
depends upon several additional extracellular molecules including lipid-binding protein 
(LBP), CD14 and MD-2 that associate with TLR4 (22, 23). Lipid-binding protein (LBP), 
a plasma protein that binds the lipid A moiety of LPS and forms a complex that can lead 
to the recruitment of another LPS-binding molecule, CD 14 (21). Subsequent studies 
have identified that MD-2 is critical for optimal LPS-mediated NF-KB activation as well 
as surface expression of TLR4 (24). Upon activation of TLR4 by LPS, the 
TolllInterleukin-l receptor (TIR) domain, a conserved intracellular domain shared by all 
TLRs, recruits the adaptor, myeloid differentiation 88 (MyD88), which can then lead to 
the activation of several signal transduction that mediate various aspects of host defense 
(25,26). 
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Stimulation of the TLR4 complex by LPS can trigger a potent inflammatory 
response that can be classified as MyD88-dependent or MyD88-independent (27). The 
adaptor protein My D88 is utilized by most TLRs (except TLR3) to initiate the host 
inflammatory response via the recruitment of various downstream signaling molecules 
including lRAK-4, lRAK-l, TRAF6, and activation of the NF-KB complex (28). 
Although MyD88 plays a critical role in mediating the production of most pro- and anti-
inflammatory cytokine production, studies using mice deficient in MyD88 have 
demonstrated the existence of a MyD88-independent pathway that regulates the 
production of type 1 interferons, including IFN-a and IFN-[3 upon TLR3- or TLR4-
stimulation (29, 30). This is characterized by delayed activation of NF-KB, MAPK(30), 
production oflFN-a/[3, Statl (Tyr70l), RANTES, IP-lO (27), and the upregulation of co-
stimulatory molecules. In this regard, studies by two laboratories demonstrated that the 
TIR-containing adaptor protein TRIF was responsible for the activation of the TLR4-
mediated MyD88-independent pathway (31, 32). Furthermore, the ability of TLR4 to 
induce type I interferon in the absence of MyD88 has been shown to be dependent upon 
the recruitment of an additional adaptor molecule called TRIF -related adaptor molecule 
(TRAM) (33). The regulation of many MyD88-iridependent responses, including type I 
interferons, has been shown to be critically dependent upon the transcription factor IRF3. 
IRF3 is ubiquitously expressed in an inactive form in the cytoplasm (28). Upon TLR4-
signaling, TBK-1 and IKK-E have been shown to phosphorylate IRF3 on specific serine 
residues and are believed to function as the IRF3 kinases (34, 35). Indeed, upon 
phosphorylation, IRF3 undergoes homodimerization, translocates to the nucleus, 
associates with and activates a transcriptional complex involving the nuclear co-activator 
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of transcription CBP/p300 that initiates the transcription of type I IFNs (36). 
The PI3K pathway and function of GSK3 in the host inflammatory response 
Mammalian PI3Ks can be divided into three classes I, II, and III based on their 
primary sequences, mechanisms of regulation, and specificities of substrates they 
phosphorylate (37, 38). Class I PI3Ks exist as heterodimers consisting of one of four 
catalytic subunits (p 11 Oa,~,('),y) and one of two families of regulatory subunits (p8Sa,~) 
(39). This class of PI3K acts on phosphatidylinositol 4,S-bisphosphate (PIP2) to produce 
phosphatidylinositol 3,4,S-trisphosphate (PI(3,4,S)P3 (PIP3), and this process is reversed 
by the phosphatase PTEN that converts PIP3 to PIP2 (40). Class II PI3 Ks phosphorylate 
phosphatidylinositol and phosphatidylinositol 4-phosphate and class III PI3Ks 
phosphorylate only phosphatidylinositol to generate phosphatidylinositol 3-phospate (37). 
The PI3K pathway has been shown to be activated by various TLR ligands and can 
function as a positive or negative regulator of TLR responses depending on the cell type 
and the TLR agonists used (41). Of the multiple forms of phosphatidylinositol-3 kinases, 
the class IA PI3K consists of heterodimers made up of a p8S regulatory and a plIO 
catalytic subunit (42). Cytoplasmic PI3K can bind to and associate with phospho-receptor 
tyrosine kinase residues as well as adaptor molecules at the plasma membrane (42). Upon 
activation, PI3K phosphorylates and converts plasma lipid membrane phosphatidyl 
inositol 4,S-biphosphate (PIP2) to phosphatidyl inositol 3,4,S-triphosphate (PIP) which 
will recruit signaling proteins containing pleckstrin-homology (PH) domains like Akt, 
PDKland PDK2 (42). Association with PDK1I2 leads to the phosphorylation of Akt. 
Dual phosphorylation of Akt (Thr308/Ser473) leads to full activation and its ability to 
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subsequently phosphorylate downstream kinases, including the glycogen synthase kinase 
3 ~ (GSK3 ~) (43). 
GSK3 is a multifunctional serine/threonine kinase within the PI3K pathway and 
has been identified in all eukaryotic organisms (44). Although initially named due to its 
ability to phosphorylate glycogen synthase, GSK3 has subsequently been demonstrated to 
phosphorylate more than 40 different substrates (45). Thus, GSK3 activity can affect a 
number of different cellular processes and has been implicated in human diseases like 
Alzheimer's disease, diabetes, and various cancers (46). There are two highly 
homologous forms of GSK3 protein, GSK3u and GSK3~, which are critical factors 
involved in the regulation of a wide variety of signaling proteins and transcription factors 
including c-Jun, c-myc, cAMP response element binding protein, cyclin D 1, cyclin E ~­
catenin and NF-AT (47). Despite their homology, GSK3u and GSK3~ are not 
functionally redundant, as mice deficient in the beta isoform die on embryonic day 16 
due to liver degeneration while the alpha isoform cannot compensate for this deficiency 
(48). GSK3 is a constitutively active kinase but can be inactivated by site specific serine 
phosphorylation (49). Phosphorylation GSK3~ at Ser9 or GSKu at Ser 21 causes the N-
terminus of GSK3 occupy the priming site which impedes the substrate's accessibility to 
the active site of GSK3 (50). GSK3 does not auto-phosphorylate the Ser9/21 sites; 
Instead, other kinases like Akt (PKB), PKA, and P90RSK have been shown to 
phosphorylate GSK3, resulting in its inactivation (51) (52) (53). The consensus sequence 
for a GSK3 substrate is Ser/Thr-X-X-X-Ser/Thr, where the first Ser/Thr is the target 
residue for phosphorylation by GSK3 and X is any amino acid (54-56). Although GSK3 
can phosporylate "non-primed substrates, if the second Ser/Thr has been phosphorylated 
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by another "priming kinase", the efficiency of GSK3 phosphorylation IS greatly 
increased. 
Previous studies have demonstrated that the phosphatidylinositol-3 kinase (PI3K) 
pathway plays a fundamental role in regulating the host inf1ammatory response to a 
variety of TLR agonists (57-59). Our previous findings identified that the constitutively 
active serine/threonine kinase, glycogen synthase kinase 3 (GSK3), was the central 
kinase responsible for the ability of this pathway to differentially regulate the production 
of pro- and anti-inf1ammatory cytokines by TLR-stimulated innate immune cells (60). 
Moreover, we demonstrated that inhibition of GSK3~ regulates the inf1ammatory 
response via enhanced activation of CREB (S133) which displaces NF-KB p65 from 
binding to the common transcription factor CREB-binding protein (CBP) (60). Although 
GSK3~ plays a central role in regulating the production of MyD88-dependent cytokines, 
the ability of GSK3 to influence MyD88-independent cytokines, i.e. interferon beta 
(IFN~), and whether GSK3~ plays a functional role in the IFN~ signaling pathways 
induction of IL-IO are still largely unknown. Therefore, the work described in this 
dissertation focused on answering these two questions. 
Induction of Interferon beta (IFN ~) and its regulation 
IFN a/~ are classified as type I interferons (IFN s) (61) and have been extensively 
used to treat a variety of human diseases including multiple leukemia, chronic hepatitis B 
and C (62-64). Moreover, IFN-~ has been regarded as the first choice for the initial 
treatment of relapsing remitting multiple sclerosis (MS)(65-67). Macrophages have been 
shown to be a major cellular source of IFN-a/~ in the immune system, however, it has 
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also been demonstrated that IFN~ can be produced by other immune cells including, 
dendritic cells, fibroblasts, NK cells, and T cells in response to both pathogen nucleic 
acids and bacterial cell wall components such as lipopolysaccharide (LPS) (68). In innate 
immune cells, pattern-recognition-receptors (PRRs) are involved in the induction of 
IFN~, including Toll-like receptors (TLRs) and RIG-I-like receptors (RLRs). Five TLRs 
(TLR3, TLR4, TLR7, TLR8, TLR9) have been shown to potently promote type I IFNs 
(69). Four of these TLRs, TLR3, TLR7, TLR8, and TLR9, can be stimulated by nucleic 
acid agonists produced during viral or bacterial infections (70). Specifically, TLR3 can 
be activated by double stranded RNA (71); TLR7 and TLR8 (in humans only) can be 
activated by antiviral derivatives of nucleoside-like imidazoquinoline (72, 73), loxoribine 
(74) and GU-rich single-stranded (ss) RNAs (75-77). TLR9 can be activated by non-
methylated double-stranded (ds) CpG-rich DNA (78, 79). TLR4, which recognizes LPS, 
can also induce the production of type I IFNs (80-82). 
The production of Type I IFNs has been demonstrated to be regulated at multiple 
steps, which include cellular processes involved both transcriptional and post-
translational mechanisms (83-85). The enhancesome of interferon beta is the best model 
to understand the multiple levels of regulation involved in the production of type I IFNs. 
A multi-protein complex called an enhanceosome is assembled at the IFNP promoter in 
response to a viral or bacterial challenge (86). The enhanceosome consists of at least 
three families of transcription factors - ATF-2/c-Jun, nuclear factor (NF)-KB and 
interferon regulatory factor (IRFs). Of these, the activities of NF-KB and IRF3 are 
regulated by their subcellular localization and site-specific phosphorylation (87, 88). In 
the inactive state, NF-KB is held in the cytosol by inhibitory KB (IKB) family members 
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(89). Upon cellular stimulation, such as IL-l~, TNF-a, and bacterial or viral components, 
the IKB kinase (IKK) is activated and phosphorylates IKB. Once phosphorylated, IKB is 
ubiquitinated and subsequently degraded by the proteasome (89), free NF-KB then 
translocates into the nucleus and turns on its target genes. Similar to NF-KB, the inactive 
form of IRF3 is also cytosolic. In response to a bacterial or viral challenge, IRF3 is 
phosphorylated by the IKK-like kinases TBK-1 and IKK£ (34, 35). Phosphorylation of 
IRF3 leads to its dimerization and translocation into the nucleus. Viral infection also 
leads to activation of stress kinases such as JNK and p38 kinase, which phosphorylate 
ATF2/c-Jun in the nucleus (90). Together, with the nuclear architectural protein HMG-I 
(Y), NF -KB, IRF3 and ATF2/c-Jun assemble into a stereo-specific enhanceosome 
complex that remodels the chromatin within the promoter region of IFN~, resulting in its 
transcriptional initiation (91, 92). 
Type I IFN signaling and IL-IO production 
All type I IFNs are genetically and structurally similar and utilize the same 
receptor, IFNAR, that is composed of two subunits, IFNARI and IFNAR2 (93). Both 
subunits are necessary for most IFN-mediated cellular functions and if either of them is 
deficient, there is no high-affinity ligand binding and little to no biological effects (94). 
Type I IFNs have been shown to have a variety of cellular properties including antiviral, 
anti-proliferation, induction of apoptosis, and immunoregulation of both the innate and 
adaptive immune compartments (94, 95). Recently, type I IFNs have also been 
demonstrated to exert potent anti-inflammatory properties (96). 
The major intracellular signaling pathway used by Type I IFNs is the Janus 
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kinase-signal transducers and activators of transcription pathway (JAK-STAT) (97). 
IFNARI and IFNAR2 constitutively bind to a single specific member of the Janus Kinase 
(JAK) family, Tyk2 and Jak 1, respectively (97). Ligand binding induces the 
phosphorylation of Jakl and Tyk2, which leads to the activation of signal transducer and 
activator of transcription 1 (STAT1) and STAT2 to form a STAT1:STAT2 heterodimer 
that associates with the transcription factor interferon regulatory factor 9 (lRF9) to form a 
complex which binds to IFN-stimulated response elements (ISREs) present in the 
promoters of many IFN-stimulated genes (lSGs) (94), thereby inducing gene 
transcription. 
IL-IO has been shown to be a prototypical immunosuppressive cytokine produced 
by T cells, B cells, dendritic cells, and monocytes/macrophages (98). Interestingly, type I 
IFN s have been reported to playa crucial role in regulating the production of IL-l 0 by 
innate immune cells (99, 100). Previous studies by Chang et al. have demonstrated the 
fundamental role IFN-P plays in regulating the levels of IL-l 0 produced by Toll-like 
receptor (TLR)-stimulated innate immune cells (l 01). Several other studies have 
additionally shown that IFN-P can modulate the immune response to other cellular 
stimuli by positively controlling the production of IL-IO (102-104). Due to their 
immunomodulatory properties, type I IFNs have also been studied extensively for the 
initial treatment of relapsing remitting multiple sclerosis (MS) (65-67). Although the 
precise therapeutic mechanism of action of IFN-P in MS treatment is unclear, IFN-P 
treatment has been shown to increase the serum levels of IL-l 0 present in MS patients 
(100), and this effect is believed to play a fundamental role in the therapeutic value of 
type I IFN s in the treatment of MS patients (105). Despite the numerous reports linking 
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IFN -~ to the induction of IL-IO production, the underlying cellular mechanisms 
responsible for the ability of IFN-~ to induce IL-l 0 production is unresolved. 
The following chapters detail our studies on the functional role of GSK3 ~ in 
TLR4-induced IFN~ production and its regulatory role in the IFN~ mediated signaling 
pathway. In the first part of my project, we demonstrated that GSK3~ activity plays a 
fundamental role in controlling the production of the MyD88-independent cytokine, IFN-
~, by TLR4-stimulated innate cells and also defined the cellular mechanism by which 
GSK3 regulates the production of IFN~. In the second part of my project, we have 
elucidated and characterized how IFN~ signaling in innate immune cells is able to induce 




INTERFERON-BETA PRODUCTION BY TLR4-STIMULATED INNATE 
IMMUNE CELLS IS NEGATIVELY REGULATED BY GSK3-BETA 
Introduction 
Toll-like receptors (TLRs) are type I transmembrane receptors involved in the 
recognition of highly conserved microbial components (106). Activation of TLRs on 
innate immune cells can result in the recruitment of different downstream signaling 
adaptors that impart selectivity on the repertoire of cytokines produced (106). In this 
regard, the TLR4-signaling pathway can activate distinct innate immune responses via 
the recruitment of the adaptor molecules TlRAP-MyD88 or TRAM-TRIF (32, 33, 107, 
108). The production of pro- and anti-inflammatory cytokines by TLR4-stimulated 
innate immune cells has been shown to be dependent upon signaling events initiated by 
TlRAP-MyD88 (107-109). In contrast, the recruitment of the adaptor molecules TRAM 
and TRIF mediate a signaling cascade involving the activation of the two non-canonical 
IKB kinases, TBK-l and IKK-E, as well as the phospho-specific post-translational 
modifications of the transcription factors NF-KB, ATF-2/c-Jun, and IRF-3 that culminates 
in the production of type I interferons (IFNs), including IFN-f3 (31-33,110). Although 
the molecular mechanisms regulating NF-KB and IRF-3 activity, as well as their 
involvement in controlling IFN-f3 production by TLR4-stimulated innate immune cells 
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have been well described, the upstream signaling events that regulate the levels and 
activity of the transcriptional complex, ATF-2/c-Jun, and the role this complex plays in 
controlling IFN-~ production by TLR4-stimulated cells is poorly understood. 
Stimulation of TLR4 can activate the phosphatidylinositol-3 kinase (PI3K) 
pathway, which restrains the MyD88-dependent production of pro-inflammatory 
cytokines (57, 58, 111). In the presence of MyD88, the ability of the PI3K pathway to 
negatively regulate the production of pro-inflammatory cytokines, while augmenting the 
levels of the anti-inflammatory cytokine, IL-IO, is due to its ability to inactivate the 
constitutively active serine/threonine kinase, GSK3-~ in TLR4-stimulated cells (58, 60, 
112, 113). The serine 9 mediated inactivation of GSK3-~ results in the alteration of the 
transcriptional complex involving the co-activator of transcription CBP, and the 
transcription factors CREB and NF-KB (60). Although GSK3-~ has been shown to 
regulate MyD88-dependent cytokine responses, whether GSK3-~ plays a functional role 
in the regulation of the prototypical MyD88-independent cytokine, IFN-~, is currently 
unknown. 
In the present study, we show that GSK3-~ activity plays a fundamental role in 
regulating IFN-~ production. Specifically, we show that the phosphorylation of GSK3-~ 
(S9) in LPS-stimulated macrophages occurs in the absence of MyD88. Inhibition of 
GSK3-~ activity potently augmented the levels of IFN-~ in LPS-stimulated innate 
immune cells, whereas the ectopic expression of a constitutively active GSK3-p mutant 
reduced IFN-~ production. Inhibition of GSK3-p was found to control the cellular levels 
of the transcription factor c-Jun and this was demonstrated to be necessary for the ability 
of GSK3 to control IFN-~ production. The functional role of GSK3-~ in regulating IFN-
13 
~ was confirmed in vivo in which the inhibition of GSK3-~ potently enhanced the 
systemic levels of IFN-~ in mice administered LPS. Taken together, these findings 
identify GSK3-~ as a critical regulatory kinase controlling IFN-~ production. 
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Materials and Methods 
Mice and reagents 
C57BLl6 mice were purchased from The Jackson Laboratories. B6.MyD88-1- mice were 
a gift from Shizuo Akira (via Ross Kedl, 3M Corporation) and were backcrossed > 6 
generations onto the C57BLl6 background. Mice were housed in a specific pathogen-
free facility at the University of Louisville School of Medicine and the University of 
Louisville Institutional Animal Care and Use Committee approved all animal protocols. 
Ultra pure LPS from E. coli was purchased from Invivogen. All antibodies and 
recombinant cytokines were obtained from Cell Signaling Technology and R&D 
Systems, respectively. The anti-HA antibody used for immunoblots was purchased from 
eBioscience. The GSK3-specific inhibitor SB216763 was previously characterized and 
was shown to be highly specific for GSK3 without discernible effects on a panel of 24 
other kinases (114). SB216763 was purchased from Tocris. siRNAs were purchased 
from Dharmacon. The plasmid pcDNA3-GSK3~(S9A) and pcDNA3-GSK3~(K85A) 
were obtained from Addgene (plasmid numbers 14754 and 14755) and originally created 
by Dr. James Woodgett's laboratory (115). The nuclear levels ofNF-KB p65 and IRF-3 
were measured using the TransAM kit purchased from Active Motif. The amount of 
nuclear NF-B p65 or IRF-3 was normalized by the absorbance at 450 nm from 10 fAg 
(NF-B p65) or 20 fAg of nuclear lysate (IRF-3). 
Cell preparation 
Bone marrow derived macrophages (BM-DM) were prepared by culturing bone marrow 
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from the femursltibiae of 6-1O-wk-old mice in RPMI 1640 containing 5% FBS, 2 mM L-
glutamine, 1 mM sodium pyruvate, 50 Ulml penicillin, 50 "",g/ml streptomycin, 10 nglml 
M-CSF, and 30% L929 conditioned medium. Non-adherent cells were collected after 24 
h and cultured for 7 days in Costar ultra low attachment polystyrene culture dishes with a 
media change on day 4. BM-DM were >85% CD 11 b +, as demonstrated by flow 
cytometry. 
In vivo levels of IFN-J3 
Male C57BLl6 mice (8-12 weeks of age; 20-28 g body weight) were injected 
intraperitoneally with a 5 "",gig of LPS in 100 "",1 of PBS containing 0.1 % DMSO. Mice 
were analyzed for systemic levels of IFN-/3 6 h after being administered LPS in the 
presence of 0.1% DMSO or 10 "",gig of SB216763. The Institutional Animal Care and 
Use Committee of the University of Louisville approved all studies. 
Transfections and IFN-J3 production 
BM-DM were transfected with non-targeting control (Ctrl) siRNA, siRNA-c-Jun, siRNA-
GSK3-/3, pcDNA3-GSK3/3CS9A), pcDNA3-GSK3/3(K85A), or pcDNA3 (empty vector 
control) using Lipofectamine RNAiMAX (Invitrogen), or Lipofectamine LTX 
(Invitrogen) following the manufacturer's protocol. The levels of total c-Jun and GSK3-
/3 protein were assessed by Western blot on day 3. 2 x 105 BM-DM were cultured in 96-
well plates and pre-treated for 2h with 0.01% DMSO (organic solvent control for 
SB216763) or the GSK3 inhibitor SB216763 (SB216763 at 12 "",M) prior to LPS (1 
"",g/ml) stimulation. Transfected BM-DM were stimulated with LPS on day 3 post-
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transfection. Cell-free supernatants were assayed for IFN-~ levels by ELISA 20 h after 
the addition ofLPS (R&D Systems). 
RT-PCR, immunoprecipitation, immunoblots and statistical analysis 
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) and real-time PCR was 
performed using an AB! 7500 system. GAPDH was used as the endogenous control and 
fold increase was calculated according to DDCT method. At the indicated time points, 
cells were harvested and analyzed by immunoblot or immunoprecipitation as previously 
described (60, 111). The Kodak 4000MM image system was used for obtaining all 
images and densitometer scans of the blots. The mouse True Blot kit (eBioscience) was 
used for all immunoprecipitations according to the manufacturer's protocol. A rabbit 
isotype control IgG antibody (Cell Signaling Technology) was used for all 
immunoprecipitations to ensure that the immunoprecipitation of ATF-2 and subsequent 
immunodetection of c-Jun were not due to non-specific interference. Data are expressed 
as mean ± SD of a minimum of three experiments. Statistical significance between 
groups was evaluated by ANOVA and the Tukey multiple comparison test (Instat 
Program). Differences were considered significant at P < 0.05. 
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Results 
TLR4-mediated phosphorylation of GSK3~ (S9) occurs in the absence of MyD88 
LPS stimulation of innate immune cells has been shown to promote GSK3-[3 
inactivation via the phosphorylation of serine 9 (S9) (58, 60). To assess whether MyD88 
is required for LPS to induce GSK3-[3 (S9) phosphorylation, wild-type and MyD88-
deficient cells were compared in their abilities to phosphorylate GSK3-[3 (S9) upon LPS 
stimulation (Fig. 1A). Both wild-type and MyD88-deficient macrophages demonstrated 
increased phospho-GSK3[3 (S9) levels after 30 and 60 min of culture in the presence of 
LPS, as compared to non-stimulated cells, (Fig. 1A). The phosphorylation of GSK3-[3 
(S9) in both wild type and MyD88-deficient cells was abrogated by the use of the PI3K 
inhibitors LY294002 or wortmannin (data not shown). A comparison of the ratios of 
phospho-GSK3-[3 (S9) to that of total [3-actin was similar between wild-type and 
MyD88-deficient cells (Fig. 1B, C). These results demonstrate that the phosphorylation 
of GSK3-[3 (S9) in LPS-stimulated macrophages occurs in the absence of MyD88. 
GSK3~ negatively regulates TLR4-induced IFN-fJ production 
Since LPS induced the phosphorylation of GSK3-[3 (S9) in the absence of MyD88 
(Fig. 1), we next investigated whether GSK3 played a role in the production of the 
MyD88-independent cytokine, IFN-[3. Pharmacological inactivation of GSK3 using the 
GSK3 inhibitor SB216763 (114) resulted in the loss of the GSK3-specific substrate 
phospho-glycogen synthase (Ser6401641), demonstrating the ability of SB216763 to 
18 
inactivate endogenous GSK3 activity In macrophages (Fig. 2A). GSK3-inactivated 
macrophages stimulated with LPS produced significantly (P<0.05) more IFN-~ protein 
and mRNA, as compared to cells stimulated with LPS alone (Fig. 2B, C). Moreover, 
LPS stimulation of macrophages treated with GSK3-~-specific siRNA (>80% total 
GSK3-~ protein knockdown, (Fig. 3A) exhibited more than a 3-fold increase (P<0.05) in 
secreted IFN-~ levels, as compared to cells treated with control siRNA and stimulated 
with LPS (Fig. 3B). TLR4-stimulation of macrophages expressing a kinase dead mutant 
of GSK3-~ (K85A) inhibited endogenous GSK3 activity (Fig. 3C, D) in macrophages 
and produced significantly (P<0.05) elevated levels of IFN-~, as compared to empty 
vector transfected cells stimulated with LPS (Fig. 3E). In contrast, the ectopic expression 
of a constitutively active GSK3-~ (S9A) mutant severely attenuated the production of 
IFN-~ by LPS stimulated macrophages, as compared to empty vector transfected cells 
stimulated with LPS (Fig. 3E). Taken together, these results demonstrate that GSK3-
~ activity plays a fundamental role in controlling the production of IFN-~ by TLR4-
stimulated macrophages. 
GSK3 controls the nuclear levels of c-Junl ATF -2 complexes by regulating total c-
Jun levels 
We next examined if serine/threonine phosphorylation by constitutively active 
GSK3 could be negatively affecting a downstream signaling molecule involved in the 
control of IFN-~ production. Previous studies have shown that c-Jun is a component of 
the IFN -~ enhanceosome (116) and that GSK3 can phosphory late the transcription factor 
c-Jun on threonine 239 that, in turn, promotes c-Jun degradation (117, 118). We 
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therefore tested whether GSK3 inhibition could affect the levels of phospho-c-Jun 
(Thr239) and total c-Jun in LPS-stimulated macrophages (Fig. 4A, B). Inactivation of 
GSK3 abrogated the ability of LPS stimulation to augment the levels of phospho-c-Jun 
(Thr239) in macrophages (Fig. 4A). Furthermore, the total levels of c-Jun were 
discernibly increased in GSK3-inactivated macrophages after 60 and especially 120 min 
of culture in the presence of LPS, as compared to non-stimulated or LPS-stimulated cells 
(Fig.4B). 
Since c-Jun has been shown to form a transcriptional complex with ATF-2 (116), 
we next examined whether GSK3-inhibition influenced the nuclear levels of c-JunJ ATF-2 
complexes. Pull-down of nuclear ATF-2 and subsequent probing for associated c-Jun by 
Western blot demonstrated that GSK3 inhibition increased the total levels of c-Jun 
associated with ATF-2, as compared to the levels observed in cells stimulated with only 
LPS (Fig. 4D). Due to the transcriptional activity of c-Jun being regulated by 
phosphorylation on serines 63 and 73 (119), we also assessed the phosphorylation levels 
of these residues (Fig. 4C). Immunoprecipitation of nuclear ATF-2 and immunoblotting 
for associated levels of phospho-c-Jun (Ser63/Ser73) demonstrated that the levels of c-
Jun (Ser63) and c-Jun (Ser73) were both highly elevated, as compared to macrophages 
stimulated with LPS alone (Fig. 4C). No discernible differences were observed in the 
levels of ATF-2 between groups (Fig. 4C, D). In contrast to the increased nuclear levels 
of c-Jun observed in GSK3-inhibited macrophages stimulated with LPS, no significant 
changes in the nuclear levels of NF-KB p65 or IRF-3 were observed (Fig. 5A, B). 
Therefore, active GSK3 negatively regulates the total cellular levels of c-Jun as well as 
the nuclear levels of c-Jun associated with ATF-2 in LPS-stimulated macrophages. 
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GSK3 inhibits TLR-4 induced IFN-f:l production by regulating c-Jun levels 
To determine whether the increased c-Jun levels observed in GSK3 inhibited cells 
played a functional role in the ability of GSK3 to modulate IFN-~ levels by LPS-
stimulated macrophages, c-Jun levels were knocked down by transfecting macrophages 
with c-Jun-specific siRNA (Fig. 6A). Transfection with c-Jun-specific siRNA reduced c-
Jun levels by over 90%, as compared to non-transfected cells or cells transfected with 
control siRNA (Fig. 6A). The knockdown in c-Jun levels abrogated the ability of GSK3-
inhibition to significantly elevate the levels of IFN-~ produced by LPS-stimulated 
macrophages, as compared to control siRNA transfected cells stimulated with LPS (Fig. 
6B). In contrast, GSK3-inhibited macrophages transfected with control siRNA and 
stimulated with LPS exhibited a significant (P<0.05) increase in IFN-~ levels, as 
compared to cells treated with control siRNA and stimulated with LPS (Fig. 6B). Thus, 
the ability of GSK3 to regulate the production of IFN-~ by LPS-stimulated macrophages 
is dependent upon GSK3' s ability to modulate the cellular levels of c-Jun. 
GSK3 regulates the in vivo production of IFN-f:l 
We next wanted to determine if inhibiting GSK3 in vivo could modulate the 
induction of IFN-~ in mice given a sub-lethal dose of LPS. For this, mice were 
administered the GSK3 inhibitor SB216763 or DMSO 2 h before receiving LPS. The 
systemic levels of IFN-~ were monitored in mice 6 h after being given LPS (Fig. 7). 
Mice administered the GSK3 inhibitor SB216763 and challenged with LPS exhibited a 
significant increase in the levels of IFN-~, as compared to control mice that received 
21 
DMSO and LPS (Fig. 7). No detectable levels of IFN-~ were observed in mice given 
DMSO or SB216763 alone (Fig. 5). These findings demonstrate targeting GSK3 in vivo 
potently increases the levels of IFN-~ upon LPS challenge. 
22 
Discussion 
The TLR4-signaling pathway in innate immune cells has been shown to mediate 
the induction of two distinct molecular pathways based on the usage of MyD88. The 
ability of TLR4 to recruit TIRAP-MyD88 and TRAM-TRIF to its cytosolic domain 
results in the production of pro-inflammatory cytokines and type I IFNs, respectively (31-
33, 109, 110, 120). Past studies by our group and others have demonstrated that the 
levels of MyD88-dependent cytokines, including both pro- and anti-inflammatory 
cytokines, were intimately controlled by GSK3-~. Specifically, the inactivation of 
GSK3-~ has been shown to negatively influence the levels of pro-inflammatory cytokines 
while concurrently augmenting the levels of the anti-inflammatory cytokine IL-I0 in 
response to TLR4-stimulation (60, 112, 113). The present study extends these previous 
findings by demonstrating that the inactivation of GSK3-~ (Ser9) occurs in the absence 
of MyD88 and GSK3-~ activity was a critical component of the regulatory mechanism 
that controlled the levels of IFN-~ by TLR4-stimulated cells both in vitro and in vivo. 
Thus, while the TLR4 signaling complex can mediate the production of both pro/anti-
inflammatory cytokines and IFN-~ via the recruitment of distinct adaptor molecules 
including TlRAP-MyD88 and TRAM-TRIF (31-33,110,120), respectively, the capacity 
of GSK3-~ to regulate both MyD88-dependent (60, 112, 113) and MyD88-independent 
cytokine responses highlights the central importance that GSK3-~ plays in the regulation 
of the host innate inflammatory response. 
The identification and characterization of the downstream cell-signaling events 
regulating the IFN-~ response have been shown to involve the activation of the kinases 
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TBK-l and IKK-£ that are involved in the phosphorylation of the transcription factor 
IRF-3 and its subsequent dimerization and translocation into the nucleus (35) (121) (122). 
The critical importance of TBK-l and IKK-£ in regulating IFN-~ via IRF-3 are 
highlighted by the findings that cells deficient in IRF-3 are unable to produce IFN-
~ (123). In addition to IRF-3, studies analyzing the inf(3 promoter have revealed the 
presence of additional regulatory molecules that can bind one of the four positive 
regulatory domains within the !fn(3 promoter. In this regard, ATF-2 and c-Jun have been 
shown to bind the !fn(3 promoter via a heterodimeric complex within the positive 
regulatory domain IV of the ifn(3 promoter (116) (86) (91). Although the findings of the 
present study did not observe any discernible effects of GSK3 inhibition on the activity of 
IRF-3, the ability of GSK3 to regulate the cellular levels of c-Jun were found to be of 
critical importance for the ability of GSK3 to modulate IFN-~ production by LPS-
stimulated innate immune cells. Moreover, siRNA-mediated knockdown of c-Jun levels 
in macrophages reduced the levels of IFN-~ produced by cells stimulated with LPS. 
These findings demonstrate a fundamental role for c-Jun in the regulation of IFN-~ and 
highlight the underlying molecular mechanism by which GSK3 regulates IFN-~ by LPS 
stimulated innate immune cells. 
The ability of GSK3 activity to differentially regulate the levels of MyD88-
dependent pro/anti-inflammatory cytokines while concurrently controlling the production 
of the MyD88-independent cytokine, IFN-~, demonstrated the existence of a crosstalk 
network between these two pathways mediated by GSK3. Interestingly, the downstream 
molecular mechanism by which GSK3-~ regulated MyD88-dependent and MyD88-
indpendent cytokine responses are unique. Studies by our laboratory were the first to 
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show active GSK3-~ negatively regulated the levels of the anti-inflammatory cytokine 
IL-IO while simultaneously promoting the production of pro-inflammatory cytokines by 
TLR-stimulated innate immune cells (60). Analysis of the mechanism by which GSK3-~ 
influenced the transcriptional control of MyD88-dependent cytokines revealed GSK3 
repressed the nuclear association of the transcription factor CREB (Ser133) with the co-
activator of transcription CB P. Upon GSK3 inactivation, IL-IO production increased 
while pro-inflammatory cytokine production was severely suppressed due to the 
displacement ofNF-KB p65 from CBP by CREB (60). Although the inhibition of GSK3 
did exhibit similar effects on the nuclear levels of CREB as has been previously reported 
(60), knockdown in the levels of CREB within the context of the current study did not 
affect the ability of GSK3 inhibition to modulate IFN-~ production by LPS-stimulated 
innate immune cells (H. Wang and M. Martin, unpublished observations). However, 
GSK3 was found to also control c-Jun levels that resulted in increased nuclear levels of 
ATF-2/c-Jun complexes. siRNA-mediated gene silencing of c-Jun demonstrated that the 
ability of GSK3 to regulate IFN-~ production by TLR4-stimulated macrophages was 
dependent upon increased c-Jun levels. Thus, the ability of GSK3-~ to regulate both 
MyD88-dependent and MyD88-independent cytokine responses occur via different 
molecular mechanisms. 
In conclusion, we have demonstrated that the constitutively active kinase, GSK3, 
plays a fundamental role in controlling the production of IFN-~. Our results showed that 
the production ofIFN-~ by LPS-stimulated macrophages was regulated by the activity of 
GSK3-~ and its ability to affect the cellular and subsequent nuclear levels of the 
transcription factor c-Jun associated with ATF-2. Overall, the current findings identify 
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GSK3 as a fundamental kinase involved in the regulation of the MyD88-independent 
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Figure 1. Stimulation of macrophages with LPS induces the phosphorylation of 
GSK3-~ (S9) in both wild-type and MyD88-deficient macrophages. (A) Wild-type 
and MyD88-deficient macrophages were stimulated with 1 f,lg/ml of LPS for 30 or 60 
min. To assess phospho-GSK3-~ (S9), 15 Ilg of total cell lysate was resolved on LDS-
PAGE, immunoblotted with an anti-phospho GSK3-~ (S9) Ab, and developed by EeL. 
Immunoblots were stripped and repro bed with an Ab to total ~-actin to ensure equal 
protein loading. (B, C) Densitometer scans of phospho-GSK3-~ (S9) and total ~-actin 
were performed and recorded as the ratio of phospho-GSK3-B (S9):total ~-actin. Data 






























Figure 2. GSK~ negatively controls IFN-~ production by LPS-stimulated 
macrophages. (A) Macrophages treated with the GSK3 inhibitor SB216763 exhibited a 
loss in the phosphorylation levels of the GSK3-specific substrate glycogen synthase 
(Ser640/641). Macrophages were pre-treated with GSK3 inhibitor SB216763 for 2h and 
then stimulated with l/l-g/ml LPS. Inhibition of GSK3 augmented the (B) mRNA and (C) 
protein levels of IFN-~ produced by TLR4-stimulated macrophages. * indicates 
statistically significant differences at P < 0.05 between the indicated groups. Results 
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Figure 3. LPS induced IFN ~ production is dependent on GSK3~. activity. siRNA-
mediated knockdown of (A) GSK3-~ protein levels increased the production of (B) IFN-
~ by LPS-stimulated (1 f!g/ml) macrophages. (C) HA expression levels in non-
transfected macrophages or macrophages transfected with a kinase dead (K85A) or 
constitutively active (S9A) plasmid encoding GSK3-~. Levels of HA were detected by 
Western blot 48h after transfection. (D) Expression of the kinase dead (K85A) GSK3 
mutant in macrophages inhibited the endogenous phosphorylation of the GSK3-specific 
substrate ~-catenin (Ser33/3 7/Thr41) . (E) As compared to empty vector control 
macrophages stimulated with LPS (1 f!g/ml), the const~tutively active GSK3-~ (S9A) and 
kinase dead GSK3-~ (K85A) negatively and positively, respectively, regulated IFN-~ 
production by macrophages stimulated with LPS Of!g/ml). indicates statistically 
significant differences at P < 0.05 between the indicated groups. Results represent the 
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Figure 4. GSK3 negatively affects the levels of nuclear c-Junl ATF -2 heterodimer 
com plexes by controlling total c-Jun levels. Inhibition of GSK3 attenuates the levels of 
(A) phospho-c-Jun (Thr239) and increases (B) total c-Jun levels in LPS-stimulated 
macrophages. GSK3 inhibition increases the association of (D) total and (C) phospho-c-
Jun (Ser63/73) to ATF-2 in LPS-stimulated macrophages. For A and B, celllysates were 
prepared at the given time points, and 15 ~g of total protein was analyzed by immunoblot 
using Abs to c-Jun (Thr239) or total c-Jun, stripped, and repro bed with an Ab to total ~-
I 
actin to ensure equal protein loading. (C, D) Nuclear lysates were prepared at the given 
time points, a rabbit isotype control (IC) IgG or tota~ ATF-2 was immunoprecipitated, 
and associated (C) total and (D) phospho-c-Jun (Ser63/73) were determined by 
immunoblot. (C, D) Total ATF-2 was monitored by immunoblot between groups to 
ensure equivalent pull-down of ATF-2. (C, D) No immunoreactive bands were detected 
at 43 or 48 kDa (c-Jun) or 65-75 kDa (ATF-2) when a rabbit isotype control (IC) 
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Figure 5. GSK3 has no discernible effect on the n,c1ear levels of the transcription 
factors NF -l( Band IRF -3. In contrast to the effect o~ GSK3 inhibition of c-Jun, GSK3 
inhibition did not discernibly affect the nuclear levels of the transcription factors (A) NF-
KB or (B) IRF-3. The transcription factor binding levels of (A) NF-KB p65 using 10 Ilg 
of nuclear lysate or (B) IRF-3 using 20 Ilg of nuclear lysate were obtained from 
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Figure 6. GSK3 controls IFN-~ production by ~egulating c-Jun levels in LPS-
stimulated macrophages. (A, B) The siRNA-mediated knockdown in c-Jun protein 
levels abrogates the ability of GSK3 inhibition to augment IFN-~ production by LPS-
stimulated macrophages (1 !--lg/ml). For A, total c-Jun levels were determined 72 h post-
transfection by immunoblot. For B, cell-free supernatants were harvested 20 h after LPS 
stimulation (1 !--lg/ml) and analyzed for IFN-~ levels qy ELISA. • indicates statistically 
significant differences at P < 0.05 between the indic(lJted groups. Results represent the 














Figure 7. Inhibition of GSK3 augments the systemic levels of IFN-f3 by mice given 
LPS. Intraperitoneal administration of the GSK3 inhibitor SB216763 (1 a ~g/g) 
significantly increased the levels of IFN-~ by mice given 5 flg/g of LPS . Results 
represent the mean ± SD of five mice/group. In vivo levels of IFN-~ in plasma were 
measured by ELISA 6 h after mice were given LPS. Sham-immunized mice were given 
PBS containing 0.1 % DMSO. • indicates statistically significant differences at P < 0.05 
compared with control mice given LPS containing 0.1 % DMSO. All groups of mice 
were given PBS containing 0.1% DMSO with or without LPS or SB216763. 
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INTERFERON-BETA INDUCES IL-IO PRODUCTION BY REGULATING 
GLYCOGEN SYNTHASE KINASE-3 BETA 
Introduction 
Interferon-f3 (IFN-f3) is a member of the type I IFN cytokine family (61). Although 
originally identified as playing a critical role in anti-viral immunity, type I IFNs are now 
recognized as important immunomodulators that playa crucial role in both the innate and 
adaptive immune systems (94, 95, 124). In this regard, past studies have highlighted the 
importance of type I IFNs in mediating the production of the anti-inflammatory cytokine 
IL-lO by innate immune cells (99, 100). Previous studies by Chang et al (101) have 
demonstrated a fundamental role for IFN-f3 in regulating the levels of IL-1 0 produced by 
Toll-like receptor (TLR)-stimulated innate immune cells. Several other studies have 
additionally shown that IFN-f3 can modulate the immune response to other cellular 
stimuli by positively controlling the production of IL-10 (102-104). Due to their 
immunomodulatory properties, type I IFNs have also been extensively for the initial 
treatment of relapsing remitting multiple sclerosis (MS) (65-67). Although the precise 
therapeutic mechanism of action of IFN-f3 in MS treatment is unclear, IFN-f3 treatment 
has been shown to increase the serum levels of IL-l 0 present in MS patients (100), and 
this effect is believed to play a role in the therapeutic value of type I IFNs in the 
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treatment of MS patients (105). Despite the numerous reports linking IFN-~ to the 
induction of IL-l 0 production, the underlying cellular mechanisms responsible for the 
ability of IFN-~ to induce IL-1 0 production remains unresolved. 
Previous studies have shown that type I IFNs can engage several signaling pathways 
including the Janus kinase-signal transducers and activators of transcription (JAK-
STAT), p38 mitogen-activated protein kinase (MAPK), and phosphoinositide 3-kinase 
(PI3K) pathways (97, 125, 126). The ability of type I IFNs to activate multiple signaling 
cascades is likely responsible for their pleiotropic biological effects on the immune 
system. Past studies by several groups have demonstrated that type I IFNs can induce the 
activation of the PI3K pathway and mediate the phosphorylation of several downstream 
kinases within this pathway, including AKT, mTOR, and p70S6K (51-53). Although 
previous studies have demonstrated a central role of the PI3K pathway in the regulation 
of IL-IO by Toll-like receptor (TLR) stimulated innate immune cells (111, 127), the 
functional role this pathway plays in the ability of type I IFNs to promote IL-10 
production by innate immune cells has not been previously investigated. 
Glycogen synthase kinase 3 (GSK3) is a constitutively active serine/threonine kinase 
that is downstream of the PI3K1 AKT pathway, and exists as two major isoforms, GSK3-
a and GSK3-~ (50). GSK3 has been recognized as a key regulator in a diverse number of 
biological processes, including the regulation of the host inflammatory response (60, 128, 
129). Specifically, past studies by our laboratory and others have demonstrated the 
pivotal role GSK3-~. plays in controlling IL-I0 production by TLR-stimulated cells. 
Given the importance of GSK3 in regulating IL-10 production (60, 113, 130), and the 
ability of type I IFNs to activate the PI3K pathway (131, 132), we investigated whether 
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type I IFNs regulated the activity of GSK3 and if this process played a functional role in 
their ability to induce IL-l O. 
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Materials and Methods 
Media and Reagents. 
Cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 50 )lM 
2-mercaptoethanol, 1mM sodium pyruvate, 2 mM L-glutamine, 20 mM HEPES, 50 Ulml 
penicillin, and 50 )lg/ml streptomycin. Ultra pure LPS from E. coli 011 J :B4 was 
purchased from Invivogen. Neutralizing anti-IFN-j3 antibody was purchased from R&D 
Systems. All other antibodies and recombinant human IFN-j3 were obtained from Cell 
Signaling Technology and R&D Systems, respectively. Recombinant human interleukin-
4 (rhIL-4) and recombinant granulocyte macrophage-colony stimulating factor (rhGM-
CSF) were purchased from R&D Systems. The GSK3 inhibitor SB216763 was 
previously characterized and was shown to be specific for GSK3 without discernible 
effects on a panel of24 other kinases (114). SB216763 and wortmannin (PI3K inhibitor) 
were purchased from Tocris and LC Laboratories, respectively. Non-targeting pools of 
siRNA and a mixture of four pre-validated siRNA duplexes specific for GSK3-b (ON 
TARGET-plus™) were purchased from Dharmacon. TaqMan probes were purchased 
from Applied Biosystems. The plasmid pcDNA3-GSK3-p(S9A) and pcDNA3-GSK3-
p(K85A) were obtained from Addgene (plasmid numbers 14754 and 14755) and 
originally created by Dr. James Woodgett's laboratory (115). Lipofectamine RNAiMAX 
and Lipofectamine LTX were obtained from Invitrogen. 
Human monocyte derived dendritic cells. 
Peripheral blood mononuclear cells (PBMCs) were obtained from healthy donors 
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as per protocols approved by the University of Louisville, Institutional Review Board, 
Human Subjects Protection Program, study number 503.05. Monocytes were isolated by 
negative selection using the human monocyte isolation kit II from Miltenyi Biotec 
Incorporated. The purity of monocytes was routinely > 90%, as determined by flow 
cytometry using a FITC-Iabeled anti-CD14 antibody. Purified monocytes were cultured 
in 6-well tissue culture plates at 2x 1 06 Iml in culture medium supplemented with 50 
nglml of rhGM-CSF and 100 nglml of rhIL-4. The medium was replaced on day 4. On 
day 9, cells were harvested, washed 2 times with OPBS, and rested overnight before 
being used in experiments. On day 9, the levels of CDla were typically greater than 
80%, as determined by flow cytometry. 
Cell transfection, Western blot, and IL-IO production. 
OCs were transfected with non-targeting control (Ctrl) siRNA, siRNA-GSK3-b, 
pcDNA3-GSK-3b(S9A), pcONA3-GSK3-b(K85A), or pcONA3 (empty vector control) 
using Lipofectamine RNAiMAX or Lipofectamine LTX following the manufacturer's 
protocol (Invitrogen). Cell lysates were prepared as previously described (111) (60). 
Twenty micrograms of total cellular protein from each group was suspended in lithium 
dodecyl sulfate (LOS) butTer, heated for 10 min at 70°C, resolved by LDS-PAGE, and 
then transferred to polyvinylidene difluoride membranes using the Novex system 
(Invitrogen). Probing and visualization of immunoreactive bands were performed using 
the ECL Plus kit (Amersham Pharmacia) by following the manufacturer's protocol. 
Images were acquired using the Kodak Image Station 4000MM system (Eastman Kodak, 
New Haven, CT). For siRNA studies, the levels of total GSK3-b and b-actin were 
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assessed by Western blot on day 3. Cells were pre-treated for 2h with 0.01 % DMSO 
(organic solvent control for SB216763 or wortmannin) or the GSK3 inhibitor SB216763 
(10 mM) or wortmannin (2S0 nM) prior to IFN-~ (lOOOU/ml) stimulation. Transfected 
DC were stimulated with IFN-~ on day 3 post-transfection and cell-free supernatants 
were assayed for IL-l 0 levels by ELISA 20 h after the addition oflFN-~ (R&D Systems). 
RT-PCR and Western Blot analysis. 
RN A extraction and first strand cDN A synthesis was performed using the S Prime 
PerfectPure RNA Cultured Cell Kit and High-Capacity cDNA Archive kit (Applied 
Biosystems). Real-time PCR was performed using an ABI 7S00 system. GAPDH mRNA 
levels were determined for each time point and used as the endogenous control. Fold 
increase was calculated according to DDCT method (133). 
Flow Cytomctric Analysis 
Cells were plated at 2.Sx 105 cells/well in a 96-well flat bottom plate. Cells were 
pre-treated with the indicated pharmacological inhibitor, siRNA, or anti- IFN-~ antibody. 
For the detection of intracellular phospho-GSK3-~, cells were harvested at the given time 
points, transferred to S ml polystyrene round-bottom tubes, washed twice with 2 ml of 
FACS buffer (PBS containing 2% FBS and 0.01 % sodium azide), and then fixed by 
adding 500 ml of formaldehyde to a final concentration of 4% in PBS for 10 min at room 
temperature. Cells were washed once in PBS and re-suspended in SOO ml of 90% 
methanol and incubated on ice for 10 min. Cells were then washed in PBS containing 
2% FBS, and then re-suspended in PBS containing 2% FBS containing an anti-phospho-
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GSK3-~ antibody (Cell signaling) or isotype control antibody. Cells were incubated at 
room temperature for 30 minutes, washed twice in PBS containing 2% FBS, and 
analyzed immediately by flow cytometry. For the detection of intracellular IL-l 0 levels, 
the levels of IL-IO were assessed by adding monensin during the last 6h of a 20 h 
stimulation. Cells were fixed in 4% paraformaldehdye, permeabilized using eBioscience 
Perm buffer, and incubated with anti-human IL-IO-FITC antibody for 30 minutes. 
Samples were then washed twice with Perm buffer and analyzed immediately by flow 
cytometry. 
Statistical analysis 
Statistical significance between groups was evaluated by the analysis of variance 
and the Tukey multiple comparison test using the InStat program (GraphPad, San Diego, 




LPS-mediated IFN-j3 enhances IL-IO production from Des 
Chang et al. (l 01) recently reported that IFN-~ played an important role in the 
ability of LPS-stimulated mouse bone marrow derived macrophages to produce IL-l O. In 
order to determine whether IFN-~ mediated a similar role in human DCs, cells were pre-
treated with anti-interferon ~ or isotype control antibody for 2 h and then stimulated with 
LPS (Fig. 8A). DCs stimulated with LPS in the presence of an anti-IFN-j3 antibody 
exhibited a significant (***, P<O.OOI) decrease in the levels of IL-lO, as compared to 
cells stimulated with LPS in the presence of an isotype control antibody (Fig. 8A). 
Moreover, as determined by t10w cytometry, cells stimulated with LPS exhibited greater 
than a two-fold increase in the levels ofIL-I 0, as compared to DC stimulated with LPS in 
the presence of an anti-IFN-j3 antibody (Fig. 8B). Since these studies demonstrated that 
IFN -13 played an important role in LPS-mediated IL-IO production, we next assessed if 
IFN-j3 alone was capable of inducing IL-IO from human DC. As compared with 
untreated cells, the addition of IFN-j3 significantly (P<0.05) enhanced the production of 
IL-I0 at all concentrations tested, whereas no effect was observed with respect to the 
levels of the pro-int1ammatory cytokines, TNFu, IL-Ib, IL-12 p40, or IL-23 (Fig. 9A-D). 
These results demonstrate that IFN-j3 produced by LPS-stimulated cells, or in isolation, 
plays an important role in the ability of DC to produce IL-l o. 
IFN-j3 activates the PI3K pathway and mediates the subsequent inactivation of 
GSK3-j3 
42 
Previous studies have reported that type I IFNs can engage the PI3K pathway and 
activate downstream effector kinases, such as AKT, mTOR, and p70S6K (52) (53). 
Since the induction of IL-l 0 from innate immune cells upon TLR stimulation is critically 
dependent on the ability of PI3K pathway to mediate the phosphorylation dependent-
inactivation of GSK3 ~, we next investigated whether GSK3b is inactivated upon IFN-~ 
stimulation of human Des and if this process was dependent on the activity of PI3K. For 
this, Des were stimulated with IFN-~ in the presence or absence of a PI3K inhibitor 
(L Y294002) and the levels of phospho-Akt (Thr 308 and Ser4 73) and phospho-GSK3-~ 
(Ser9) were assessed by Western blot and flow cytometry. Optimal physiological 
activation or repression of Akt and GSK3 activity, respectively, is dependent on the 
phosphorylation of the sites Thr308 and Ser473 on Akt and Ser9 on GSK3-~(60). As 
shown in figure 10, IFN-~ stimulated Des exhibited increased levels of both phospho-
Akt (Thr308 and Ser473) and phospho-GSK3-b~ (Ser 9), as compared to non-stimulated 
cells. Furthermore, inhibition of PI3K activity abrogated the ability of IFN-~ to induce 
the phosphorylation of both Akt and GSK3-~. (Fig. 1 OA-B). We further examined the 
levels of phospho-GSK3-~ in IFN-~-stimulated Des at the single cell level by flow 
cytometry. As shown in figure 11, IFN-~ stimulation increased the percent of Des 
expressing phospho-GSK3-~ from 0.63% in the non-stimulated control cells to over 
31.3% in IFN-~ stimulated cells. Moreover inhibition of PI3K activity attenuated the 
increased levels of phospho-GSK3-b observed in IFN-~ stimulated Des. Thus, IFN-~ 
mediates the PI3K-dependent phospho-inactivation of GSK3-~ in human dendritic cells. 
Suppression of GSK3-fl activity is critical for IFN-fl-induces IL-IO production 
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Given the importance of GSK3 in regulating IL-l ° production (60, 113, 130), and 
the ability of IFN-~ to induce phospho-inactivation of GSK3-~ in a PI3K dependent 
manner (Fig. lOB), we next investigated whether this process played a functional role in 
the ability of IFN-~ to induce IL-IO from human DCs. To initially test this possibility, 
DCs were stimulated with IFN-~ in the presence or absence of a PI3K inhibitor, and the 
production of IL-l 0 was monitored by ELISA and flow cytometry. As shown in figures 
12A and B, inhibition of PI3K significantly (P<O.Ol) decreased the levels of IL-IO 
produced by IFN-~ stimulated DC. To directly assess whether GSK3 plays a functional 
role in the ability of IFN -~ to induce IL-IO, we next pre-treated human DCs with the 
GSK3 inhibitor SB216763 and subsequently stimulated with IFN-~. Inhibition of GSK3 
significantly (P<O.Ol) enhanced both the steady state levels of IL-IO mRNA and the 
amount of IL-l 0 protein produced upon IFN-~ stimulation of DCs, as compared to cells 
treated with IFN-~ alone (Fig. 12C, D). 
We next used siRNA-mediated gene silencing to confirm the functional role of 
the GSK3-~ isoform in suppressing IL-I0 production from IFN-~ treated cells. Human 
DCs exhibiting a knockdown in the cellular levels of GSK3-~ protein produced 
significantly (P<0.05) elevated levels of IL-l 0 upon stimulation with IFN-~. (Fig. 13B), 
as compared to cells transfected with non-targeting siRNA and stimulated with IFN-~. In 
addition, IFN-~-stimulation of DC expressing a kinase dead mutant of GSK3-~ (K85A) 
inhibited endogenous basal GSK3 activity (data not shown) and produced significantly 
(P<0.05) elevated levels of IL-IO, as compared with empty vector transfected cells 
stimulated with IFN-~ (Fig. 13C). In contrast, the ectopic expression of a constitutively 
active GSK3-~ (S9A) mutant severely attenuated the ability of IFN-~ to stimulate human 
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DC to produce IL-10, as compared with empty vector transfected cells stimulated by 
IFN-~ (Fig. 13C). Taken together, these results demonstrate that the repression of GSK3-
pactivity in human DCs observed upon IFN-~-stimulation is a fundamental process 
involved in the regulation of IFN-~ induced IL-1 0 production. 
IFN-~ induces partial but not complete inactivation of GSK3-b activity 
The data from the current study demonstrates that IFNb increased the 
phosphorylation of GSK3-~ (Ser9) and preventing this phospho-inactivation of GSK3-b 
abrogated the ability of IFN-~ to induce IL-10 by human DCs. Moreover, our findings 
obtained from both pharmacological inhibition and siRNA-mediated knockdown of 
GSK3 demonstrated that a further reduction in GSK3- activity enhanced the levels of IL-
10 by IFN-~-stimulated cells, as compared to cells stimulated with IFN-~ alone. Thus, as 
compared to cells stimulated with IFN-~ alone, the findings that either pharmacological 
inhibition or siRNA-mediated knockdown of GSK3 significantly (P<O.O 1) increased the 
levels of IL-1 0 produced by IFN-~ stimulated cells, suggest that the differences in IL-1 0 
levels are due to differences in their ability to inactivate GSK3-~. To test this possibility, 
we monitored the relative level of GSK3 activity by assessing the phospho-levels of the 
GSK3-specific substrate, glycogen Synthase (GS) (134, 135). As compared to non-
stimulated DCs, the levels of GSK3~-mediated phospho-GS were substantially reduced 
«42%) after IFN b stimulation (Fig. 14A-B). Moreover, treatment of DCs with the 
GSK3 inhibitor SB216763 completely abrogated GS phosporylation as evident by the 
100% reduction in the phosphorylation levels of GS, as compared to non-stimulated 
controls (Fig. 14A-B). Thus, whereas IFN ~-stimulated DC did exhibit a partial 
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reduction in GSK3 activity, it did not completely abolish the activity of GSK3, as noted 
with the GSK3 inhibitor SB216763. 
IFN-~ enhances the activity of the transcription factor CREB 
The present study demonstrated that IFN-~ was capable of reducing GSK3-
bactivity and that this process was critical for the ability of IFN-~ to induce IL-IO by 
human DCs. Since GSK3-~ has previously been shown to regulate the activity of the 
transcription factor CREB and that CREB is involved in regulating IL-IO production by 
TLR-stimulated cells, we next investigated whether IFN-~-mediated GSK3 inhibition 
influenced the nuclear levels of CREB (Ser133). We have previously demonstrated that 
the inhibition of GSK3~ activity by way of TLR-stimulation leads to an increase in the 
level of nuclear phospho-CREB at serinel33. The phosphorylatio of this site has 
previously been demonstrated to enhance CREB' s interaction with the transcription 
coactivator CBP. As compared to non-stimulated control, neither the GSK3 inhibitor 
SB216763 nor PI3K inhibitor LY294002 substantially affected the levels of nuclear 
phosphorylated CREB (Ser 133) in non-stimulated cells (Fig. 14C). In contrast, the DNA 
binding properties of CREB (Ser 133) were significantly (P<O.O 1) enhanced in IFN-~ 
stimulated DC, as compared to non-stimulated control cells (Fig. 14C). Moreover, cells 
pre-treated with the GSK3 inhibitor SB216763 significantly (P<O.O 1) enhanced the 
nuclear levels of CREB(Serl33), whereas blockade of PI3K activity abrogated the ability 
of IFN-~ to increase CREB(Serl33) DNA-binding activity, as compared to cells 
stimulated with IFN-~ (Fig. 14C). These findings demonstrate that the ability of IFN-~ 
to augment the nuclear levels and DNA binding of CREB (Serl33) are dependent upon 
its engagement of the PI3K pathway and its ability to suppress GSK3 activity. 
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Discussion 
The ability of IFN-~ to induces the anti-inflammatory cytokine IL-I0 is believed 
to play a critical role in its therapeutic value for the treatment of MS (l00, 105). 
Although previous studies have documented a multitude of signaling cascades that can be 
activated by IFN-~ including the Jak-STAT, PI3K, P38, MAPKs and NF-KB pathways, 
the cellular mechanisms responsible for the ability of IFN-~ to stimulate the production 
of IL-I0 has remained largely unknown (97, 125, 126, 136). Our present findings 
demonstrated that IFN-~ activates the PI3K pathway and that this process is required for 
IFN-~ induces IL-lO production. Moreover, we demonstrated that IFN-~ is able to 
regulate the activity of the constitutively active serine/threonine kinase GSK3-Ra 
downstream signaling component within the PI3K pathway, and that the suppression of 
GSK3 activity is required for IFN-~ to induce IL-lO from human DCs. 
GSK3-~ is a constitutively activated serine/threonine kinase within the PI3K 
pathway (50). Past studies have shown that inhibiting its GSK3 kinase activity 
negatively influences the levels of proinflammatory cytokines while concurrently 
augmenting the level of the anti-inflammatory cytokine IL-I0 in TLR-stimulated cells 
(60). A recent study by Cheng et al. (101) has shown that IFN-~ produced upon LPS 
stimulation was required for LPS-induced IL-l O. However, the underlying cell-signaling 
pathway engaged by this positive feedback loop responsible for IL-l 0 induction was not 
clear. The findings of the current study extend Chang et ai's findings by demonstrating 
that the ability of IFN-~ to partially repress GSK3-~ activity is a necessary step in the 
induction of IL-l 0 upon IFN-~ stimulation. Indeed, preventing the phospho-inactivation 
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of GSK3-f3 either by blocking PI3K activity or by the overexpression of a constitutively 
active mutant of GSK3-p(S9A) inhibited the ability of IFN-f3 to stimulate IL-10 
production from human DCs. Moreover, the observed higher levels of IL-1 0 induced by 
IFN-f3 stimulation in the presence of GSK3 inhibition, as compared to IFN-f3 alone, 
suggested IFN-f3 stimulation reduces rather than abolishes the cellular pool of activate 
GSK3. Indeed, an assessment of endogenous GSK3 activity by measuring the levels of 
phospho-glycogen synthase revealed that IFN-f3 is incapable of fully inactivating GSK3 
in human DCs. Thus, although IFN-f3 mediated suppression of GSK3 activity is 
responsible for IFN - f3 's ability to induce IL-IO, this effect on IL-IO production can be 
further modulated by other stimuli that can further repress GSK3 activity. 
Type I IFNs have been shown to playa crucial role in host defenses against 
various pathogenic bacteria by differentially modulating the production of some 
important immunomodulatory cytokines (137) (138) (139). Past studies have shown that 
type I IFNs can inhibit the production of IL-12 and enhance the immunosuppressive 
cytokine IL-J 0 in vitro and in vivo (99, 104, 140). It has additionally been shown that 
IFNAR deficient mice exhibited a hyperinflammatory response in vivo to LPS challenge 
and had significantly lower levels of IL-l 0, as compared to wild-type mice (141, 142). 
Since IL-IO is a well-known immunosuppressive cytokine and plays a crucial role in 
modulating the immune response against various pathogenic bacteria (98, 143-145), our 
current findings identifying how IFN-f3 induces IL-IO production by way of GSK3-f3 
coupled with our previous work demonstrating the ability of GSK3-f3 to differentially 
regulate IL-l 0 and IL-12 levels, provides insight into the cellular mechanism responsible 
for the inhibitory effect of type I IFNs on the host inflammatory response. 
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In conclusion, the present study identified that IFN-f3 activated the PBK pathway 
and induced the partial inactivation of the constitutively active serine/threonine kinase, 
GSK3-f3. This process was found to play a critical role in the regulation of the anti-
inflammatory cytokine IL-IO production by IFN-f3-stimulated Des. Interestingly, the 
cell-signaling pathway by which IFN-f3 suppresses GSK3 activity appeared to be 
selective for the induction of IL-J 0, and thus mimics some of the characteristics GSK3 
plays in enhancing IL-IO production by TLR-stimulated innate immune cells. The 
current findings further characterized and identified the underlying cellular mechanisms 
by which IFN-f3 induces the production of IL-l 0 by innate immune cells and underscored 
the importance of GSK3 regulation in the induction of IL-l 0 by IFN-f3. Since IFN-~ 
treatment has been shown to increase the serum levels of IL-I 0 present in MS patients 
(100), and this effect is believed to play an important role in the therapeutic value of type 
I IFN s in the treatment of MS patients (105), our results indicate that GSK3 inhibition 
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Figure 8. IFN-~ is required for LPS-induced IL-IO production from DCs. (A) Des 
were pretreated with anti-IFN~ or isotype control antibody (100ng/ml) for 2h, stimulated 
for 20 h with or without LPS (1 ).lg/ml), and cell-free supernatants were analyzed for IL-
10 levels by ELISA. (B) Des were pretreated with anti-IFN~ or isotype control antibody 
for 2h and then stimulated with LPS (l).lg/ml) for 20 h. Monensin was added during the 
last 12h of the assay and cells were analyzed for intracellular IL-l 0 by flow cytometry. 
(C) Des were stimulated with the indicated concentration of IFN-~ for 24 h and cell-free 
supernatants were analyzed for IL-IO by ELISA. *, p<O.OI as determined by ANOVA 
and post hoc Tukey test. Data represent the mean ±SD of three separate experiments. 
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Figure 9. DCs were pretreated for 2 h with DMSO (0.1%), SB216763 (12IlM) or 
L Y294002 (50IlM) and then stimulated with IFN-B (5000 IU/ml)_ Cell-free supernatants 
were collected 20 h after IFNB stimulation and assayed for TNF-a (D), IL-l B (E) , IL-23 
(F), and IL-12p40 (G) levels by ELISA. *,p<O.Ol as determined by ANOVA and post 
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Figure 10. IFN-~ induces PI3K-dependent phosphorylation of Akt and GSK3~ in 
DCs. Des were pretreated with the PI3K inhibitor, LY294002 (50f-1,M), or DMSO 
(0.1 %) for 2 h and then stimulated with IFN-~ for 30 or 60 min. Total cell lysates were 
probed for phospho-Akt (S473 or T308) (A) or phospho-GSK3~ (S9) (B) levels by 
Western blot and subsequently repro bed for total GSK3-~ and total ~-actin . (C) 
Densitometry scans of total and phospho-GSK3~ (S9) were performed and recorded as 
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Figure 11. Des were pretreated for 2h with LY294002 (50flM) or DMSO (0.1 %) and 
then stimulated with IFN-~ for 60 min and the levels of phospho-GSK3~ (S9) were 
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Figure 12. Regulation of IFN-~ induced IL-I0 production by PI3K and GSK3. (A) 
DCs were pretreated for 2h with DMSO (0.1 %) or LY294002 (50flM) and then 
stimulated with IFN ~ (5000 IU/ml) for 20h with the resultant Cell-free supernatants 
were analyzed for IL-l 0 levels by ELISA. (B) DCs were stimulated as indicated above 
with the exception that monesin was added during the last 12 hours of stimulation and 
cells were subsequently analyzed for intracellular IL-10 by flow cytometry_ (C and D) 
DCs were pretreated for 2h with DMSO (0.1%) or SB216763 (12flM) and then 
stimulated with IFN-~. IL-10 protein and steady-state mRNA levels were determined by 
ELISA following a 20h stimulation and by RT-PCR, respectively. *, p<0_01 as 
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Figure 13. IFN-j3 induced IL-IO production is dependent on GSK3j3 activity. (A) 
DCs were either mock transfected, transfected with nontargeting siRNA, or transfected 
with GSK3f3-specific siRNA. Cellular lysates were prepared and day 3 and analyzed by 
Western blot. (B) Transfected cells were stimulated with IFN-f3 and IL-IO levels from 
cell-free supernatants were analyzed by ELISA. (C) DCs were transfected with pcDNA3 
(empty vector control), pDNA3 encoding a constitutively active mutant of GSK3-f3 
(S9A), or pcDNA3 encoding a kinase dead mutant of GSK3-f3 (K85A). On day 2, 
transfected cells were stimulated for 20h with IFN-f3 and IL" 1 0 levels from cell-free 
supernatants were analyzed by ELISA. *,p<O.Ol as determined by ANOVA and post hoc 
Tukey test. Data represent the mean ±SD of three separate experiments. 
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Figure 14. IFN-~ stimulation of Des alters the phospho-levels of the GSK3~ 
substrates glycogen synthase and eREB. DCs were pretreated with DMSO (0.1 %), the 
GSK3 inhibitor SB216763 (12f-lM), or the PI3K inhibitor LY294002 (50f-lm) and then 
stimulated with IFN-~. (A) Cells was harvested after 30 min stimulation and probed for 
phospho-Glycogen Synthase (Ser641) and ~-actin by Western blot. (B) Densitometer 
scans of blots from Figure 14A. (e) Nuclear extracts (10 f-lg) were prepared from DCs 
after IFN ~ stimulation and analyzed for binding activity of CREB using an ELISA-based 
transcription factor binding assay. *, p<O.O 1 as determined by ANO VA and post hoc 
Tukey test. Data represent the mean ±SD of three separate experiments. 
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MODEL FOR GSK3'S REGULATION OF IFN BETA SIGNALING 
GSK3 Regulatory role in IFN beta and IL-10 expression 
'\ 







TLRs initiate various signal transduction cascades that activate and regulate the 
host's Immune response. As a result, a common set of genes are expressed which 
produce essential molecules for the activation and the regulation of both innate and 
adaptive immunity, such as pro- and anti- inflammatory cytokines, chemokines and co-
stimulatory molecules (146-148). This resultant inflammatory response is essential for 
the eradication of infectious microorganisms. However, excessive or prolonged activation 
of TLRs can lead to detrimental inflammatory reactions, tissue/cell damage, and even 
death (149). Therefore, it is crucial to identifY and characterize specific regulatory 
molecules and pathways involved in controlling the host inflammatory response. The 
work presented herein identified two new regulatory pathways that characterized the 
cellular processes by which GSK3 regulates the production of the prototypical MyD88-
independent cytokine, IFN~, as well as how IFN~ acts via a autocrine/paracrine 
feedback mechanism to induce IL-l 0 production by innate immune cells. 
GSK3-~ is a constitutively activated serine/threonine kinase within the PI3K 
pathway (50). Past studies have shown that inhibition of GSK3 kinase activity negatively 
influences the levels of proinflammatory cytokines while concurrently augmenting the 
level of the anti-inflammatory cytokine IL-I0 produced by TLR-stimulated cells 
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(60). A recent study by Cheng et al. (101) has shown that IFN-~ was involved in the 
production of IL-10 by LPS-stimulated cells due to a positive feedback mechanism 
involving IFN~. The findings of the current study extend these findings by 
demonstrating that the ability of IFN-~ to partially repress GSK3-~ activity was 
necessary for the induction ofIL-lO by IFN -~ stimulated cells. Preventing the phospho-
inactivation of GSK3-~ inhibited the ability of IFN-~ to stimulate IL-l 0 production from 
DC. The observed increase in the levels of IL-lO induced by IFN-~ in the presence of 
GSK3 inhibition, as compared to IFN-~ alone, suggested IFN-~ alone may not have 
inactivated GSK3 to the levels mediated by the GSK3 inhibitor. Indeed, an assessment of 
GSK3 inactivation revealed that IFN-~ was capable of partially inactivating the ability of 
GSK3 to phosphorylate a specific GSK3 substrate, as compared to complete inhibition 
observed with the GSK3 inhibitor. Thus, IFN-~ mediated suppression in GSK3 activity 
is responsible for its ability to induce IL-10, and this effect on IL-10 production can be 
further enhanced by inactivating GSK3 activity. 
The identification and characterization of the downstream cell-signaling events 
regulating the IFN-~ response have been shown to involve the activation of the kinases 
TBK-1 and IKK-£ that are involved in the phosphorylation of the transcription factor 
IRF-3 and its subsequent dimerization and translocation into the nucleus (35) (121) (122). 
In addition to IRF-3, studies analyzing the inff3 promoter have revealed the presence of 
additional regulatory molecules that can bind one of the four positive regulatory domains 
within the [lnf3 promoter. In this regard, ATF-2 and c·Jun have been shown to bind the 
[lnf3 promoter via a heterodimeric complex within the positive regulatory domain IV of 
the ifnf3 promoter (116) (86) (91). Although the findings of the present study did not 
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observe any discernible effects of GSK3 inhibition on the activity of IRF-3, the ability of 
GSK3 to regulate the cellular levels of c-Jun were found to be of critical importance for 
the ability of GSK3 to modulate IFN-~ production by LPS-stimulated innate immune 
cells. Moreover, siRNA-mediated knockdown of c-Jun levels in macrophages reduced 
the levels ofIFN-~ produced by cells stimulated with LPS. These findings demonstrate a 
fundamental role for c-Jun in the regulation of IFN-~ and highlight the underlying 
molecular mechanism by which GSK3 regulates IFN-~ by LPS stimulated innate immune 
cells. 
Past studies have shown that type I IFNs could inhibit the production ofIL-12 and 
enhance the immunosuppressive cytokine IL-I0 in vitro and in vivo (99, 104, 140). It has 
additionally been shown that IFNAR deficient mice exhibited a hyper-inflammatory 
response In VIVO to LPS challenge and had significantly lower levels of IL-I0, as 
compared to wild-type mIce (141, 142). Since IL-10 IS a well-known 
immunosuppressive cytokine and plays a crucial role in modulating the immune response 
against various pathogenic bacteria (98, 143-145), our current findings identifying how 
IFN -~ induced IL-I0 production is mediated via partial inhibition of GSK3-~ and the 
ability of GSK3-~ to differentially regulate IL-l 0 and IL-12 levels, provides insight into 
the cellular mechanism responsible for the inhibitory effect of type I IFNs on the host 
inflammatory response. 
There are two major molecular pathways activated by TLR4 and are classified as 
MyD88-dependent and MyD88-independent (31, 33, 110). Previous studies by our 
laboratory and others demonstrated that GSK3 ~, a downstream serine-threonine kinase 
within the PI3K pathway, differentially regulates the levels of MyD88-dependent 
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cytokines, including both pro- and anti-inflammatory cytokines by TLR4-mediated innate 
immune cells (60). Specifically, the inactivation of GSK3-~ was shown to negatively 
influence the levels of pro-inflammatory cytokines while concurrently augmenting the 
levels of the anti-inf1ammatory cytokine IL-I0 in response to TLR4-stimulation (60). 
The current findings extend these observations by demonstrating that the inactivation of 
GSK3-~ (Ser9) occurs in the absence of MyD88 and that GSK3-~ activity was a critical 
component of the regulatory mechanism that controlled the levels of IFN-~ by TLR4-
stimulated cells both in vitro and in vivo. Interestingly, the cellular mechanisms by which 
GSK3 regulated the prototypical MyD88-independent cytokine, IFN-~, differed from that 
by which GSK3 regulates the production of MyD88-dependent pro- and anti-
inf1ammatory cytokines. In the current study, we showed that the inhibition of GSK3~ 
augmented the levels of the transcription factor c-Jun and thereby increased the amount 
of c-Jun I ATF2 complexes that were responsible for the ability of GSK3 inhibition to 
augment the production of IFN~. In contrast, GSK3 differentially regulated the 
production of MyD88-dependent cytokines via increases in nuclear levels of CREB 
(S 133) and thus enhanced the formation of the transcriptional complex CREB/CBP that 
promoted the transcriptional regulation ofIL-l 0 while attenuating the production of NF-
KB-dependent pro-inf1ammatory cytokines (60). Taken together, these studies 
highlighted the capacity of GSK3~ to regulate both MyD88-dependent (112, 113, 119) 
and MyD88-independent cytokine responses and further characterized the fundamental 
role that GSK3-~ played in the regulation of the host inf1ammatory response. 
IL-J 0 has long been recognized to be a prototypical immunosuppressive cytokine 
and involved in the regulation of immune homeostasis due to its broad anti-inf1ammatory 
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properties on cells of both innate and adaptive immune system (98). Dys-regulation of 
IL-lO has been shown to mediate or contribute to many chronic inflammatory diseases 
such as Chrohn's disease, multiple sclerosis, and allergic contact dermatitis (150). There 
are several aspects of IL-I 0 gene regulation that are conserved among all cells, while 
other mechanisms appear to be cell-type specific (151, 152). In this regard, the promoter 
region in all IL-lO-producing cells is essentially the same and the transcription factors 
that initiate IL-lO transcription are conserved (152). Transcription factors reported to 
bind the IL-IO promoter include Spl/3, STAT3, C/EBP, IRF-I, c-Maf, AP-I, CREB, and 
NF -KB (152). In contrast to these conserved transcription factors, the signaling pathways 
that induce IL-l 0 are generally unique to each cell type. In innate immune cells, several 
studies have shown that GSK3 regulated the production of IL-IO in a CBP-CREB 
dependent manner in which GSK3 inactivation increases the nuclear levels of CREB 
(Sl33) and displaces NF-KB p65 from the transcriptional complex. Subsequent studies 
have also shown that the Epstein Barr Viral Protein, LMP I, induces IL-IO production 
from B cells through the inactivation of GSK3 and an increase in CREB activity (153). 
Studies by others have confirmed these initial observations by demonstrating that GSK3 
activity regulated the IL-lO production in response to stimulation by Anti-ribosomal 
phosphoprotein autoantibodies in both macrophage cell-lines and primary human 
macrophages (130). In contrast, the cellular mechanism by which GSK3 controls IL-l 0 
production in human memory CD4+ T cells is divergent. Specifically, GSK3 inactivation 
potently increases IL-IO production by memory CD4+ T cells by increasing the cellular 
levels of the transcription factor, c-Jun. Interestingly, GSK3 inactivation in memory 
CD4+ T cells exhibited no effect on the nuclear levels or transcriptional binding 
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properties of CREB (S 133) (154). Thus, the ability of GSK3 to regulate the production 
of IL-l 0 appears to be conserved among cells comprising both the innate and adaptive 
immune compartments. However, the underlying cellular mechanisms by which GSK3 
controls IL-l 0 production in different cellular lineages differ. 
63 
REFERENCES 
1. Janeway, C. A., Jr., and R. Medzhitov. 2002. Innate immune recognition. Annu 
Rev Immunol20:197-216. 
2. Medzhitov, R. 2001. Toll-like receptors and innate immunity. Nat Rev Immunol 
1:135-145. 
3. Meylan, E., 1. Tschopp, and M. Karin. 2006. Intracellular pattern recognition 
receptors in the host response. Nature 442:39-44. 
4. Hashimoto, c., K. L. Hudson, and K. V. Anderson. 1988. The Toll gene of 
Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a 
transmembrane protein. Cell 52:269-279. 
5. Lemaitre, B., E. Nicolas, L. Michaut, 1. M. Reichhart, and 1. A. Hoffmann. 1996. 
The dorsoventral regulatory gene cassette spatzlelToll/cactus controls the potent 
antifungal response in Drosophila adults. Cell 86:973-983. 
6. Marshak-Rothstein, A., and I. R. Rifkin. 2007. Immunologically active 
autoantigens: the role of toll-like receptors in the development of chronic 
inflammatory disease. Annu Rev Immunol 25 :419-441. 
7. Tabeta, K., P. Georgel, E. Janssen, X. Du, K. Hoebe, K. Crozat, S. Mudd, L. 
Shamel, S. Sovath, J. Goode, L. Alexopoulou, R. A. Flavell, and B. Beutler. 2004. 
Toll-like receptors 9 and 3 as essential components of innate immune defense 
against mouse cytomegalovirus infection. Proc Natl Acad Sci USA 101:3516-
3521. 
8. Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like receptors. Annu Rev Immunol 
21 :335-376. 
9. Zhang, D., G. Zhang, M. S. Hayden, M. B. Greenblatt, C. Bussey, R. A. Flavell, 
and S. Ghosh. 2004. A toll-like receptor that prevents infection by uropathogenic 
bacteria. Science 303: 1522-1526. 
10. O'Neill, L. A., and A. G. Bowie. 2007. The family of five: TIR-domain-
containing adaptors in Toll-like receptor signalling. Nat Rev ImmunoI7:353-364. 
11. Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate 
immunity. Cell 124:783-801. 
64 
12. Ishii, K. 1., S. Uematsu, and S. Akira. 2006. 'Toll' gates for future immunotherapy. 
Curr Pharm Des 12:4135-4142. 
13. Akashi-Takamura, S., and K. Miyake. 2006. Toll-like receptors (TLRs) and 
immune disorders. J Infect Chemother 12:233-240. 
14. Carpenter, S., and L. A. O'Neill. 2007. How important are Toll-like receptors for 
antimicrobial responses? Cell Microbiol9: 1891-1901. 
15. Uematsu, S., M. H. lang, N. Chevrier, Z. Guo, Y. Kumagai, M. Yamamoto, H. 
Kato, N. Sougawa, H. Matsui, H. Kuwata, H. Hemmi, C. Coban, T Kawai, K. 1. 
Ishii, O. Takeuchi, M. Miyasaka, K. Takeda, and S. Akira. 2006. Detection of 
pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD 11 c+ lamina 
propria cells. Nat ImmunoI7:868-874. 
16. Lauw, F. N., D. R. Caffrey, and D. T Golenbock. 2005. Of mice and man: TLR11 
(finally) finds profilin. Trends ImmunoI26:509-511. 
17. Yarovinsky, F., and A. Sher. 2006. Toll-like receptor recognition of Toxoplasma 
gondii. Int J Parasitol 36:255-259. 
18. Kawai, T, and S. Akira. 2007. Antiviral signaling through pattern recognition 
receptors. J Biochem 141:137-145. 
19. Krieg, A. M., and 1. Vollmer. 2007. Toll-like receptors 7, 8, and 9: linking innate 
immunity to autoimmunity. Immunol Rev 220:251-269. 
20. Gorden, K. K., X. Qiu, 1. 1. Battiste, P. P. Wightman, J. P. Vasilakos, and S. S. 
Alkan. 2006. Oligodeoxynucleotides differentially modulate activation of TLR7 
and TLR8 by imidazoquinolines. J Immunoll77:8164-8170. 
21. Wright, S. D., R. A. Ramos, P. S. Tobias, R. 1. Ulevitch, and 1. C. Mathison. 
1990. CDI4, a receptor for complexes of lipopolysaccharide (LPS) and LPS 
binding protein. Science 249: 1431-1433. 
22. Guha, M., and N. Mackman. 2001. LPS induction of gene expression in human 
monocytes. Cell Signal 13:85-94. 
23. Erridge, c., S. Kennedy, C. M. Spickett, and D. J. Webb. 2008. Oxidized 
phospholipid inhibition of toll-like receptor (TLR) signaling is restricted to TLR2 
and TLR4: roles for CDI4, LPS-binding protein, and MD2 as targets for 
specificity of inhibition. J BioI Chem 283:24748-24759. 
24. Shimazu, R., S. Akashi, H. Ogata, Y. Nagai, K. Fukudome, K. Miyake, and M. 
Kimoto. 1999. MD-2, a molecule that confers lipopolysaccharide responsiveness 
on Toll-like receptor 4. J Exp Med 189:1777-1782. 
25. Dunne, A., and L. A. O'Neill. 2003. The interleukin-1 receptor/Toll-like receptor 
65 
superfamily: signal transduction during inflammation and host defense. Sci STKE 
2003:re3. 
26. O'Neill, L. A, K. A Fitzgerald, and A G. Bowie. 2003. The Toll-IL-l receptor 
adaptor family grows to five members. Trends ImmunoI24:286-290. 
27. Yamamoto, M., K. Takeda, and S. Akira. 2004. TIR domain-containing adaptors 
define the specificity ofTLR signaling. Mol ImmunoI40:861-868. 
28. Moynagh, P. N. 2005. TLR signalling and activation of IRFs: revisiting old 
friends from the NF-kappaB pathway. Trends ImmunoI26:469-476. 
29. Yamamoto, M., S. Sato, K. Mori, K. Hoshino, O. Takeuchi, K. Takeda, and S. 
Akira. 2002. Cutting edge: a novel TolllIL-l receptor domain-containing adapter 
that preferentially activates the IFN-beta promoter in the Toll-like receptor 
signaling. J ImmunoI169:6668-6672. 
30. Kawai, T, O. Takeuchi, T Fujita, 1. Inoue, P. F. Muhlradt, S. Sato, K. Hoshino, 
and S. Akira. 2001. Lipopolysaccharide stimulates the MyD88-independent 
pathway and results in activation of IFN-regulatory factor 3 and the expression of 
a subset of lipopolysaccharide-inducible genes. J ImmunoI167:5887-5894. 
31. Hoebe, K., X. Du, P. Georgel, E. Janssen, K. Tabeta, S. O. Kim, 1. Goode, P. Lin, 
N. Mann, S. Mudd, K. Crozat, S. Sovath, 1. Han, and B. Beutler. 2003. 
Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. 
Nature 424:743-748. 
32. Yamamoto, M., S. Sato, H. Hemmi, K. Hoshino, T Kaisho, H. Sanjo, O. 
Takeuchi, M. Sugiyama, M. Okabe, K. Takeda, and S. Akira. 2003. Role of 
adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. 
Science 301:640-643. 
33. Yamamoto, M., S. Sato, H. Hemmi, S. Uematsu, K. Hoshino, T. Kaisho, O. 
Takeuchi, K. Takeda, and S. Akira. 2003. TRAM is specifically involved in the 
Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat 
Immunol 4: 1144-1150. 
34. Fitzgerald, K. A, S. M. McWhirter, K. L. Faia, D. C. Rowe, E. Latz, D. T. 
Golenbock, A 1. Coyle, S. M. Liao, and T Maniatis. 2003. IKKepsilon and 
TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 
4:491-496. 
35. Sharma, S., B. R. tenOever, N. Grandvaux, G. P. Zhou, R. Lin, and 1. Hiscott. 
2003. Triggering the interferon antiviral response through an IKK-related 
pathway. Science 300: 1148-1151. 
36. Yoneyama, M., W. Suhara, and T. Fujita. 2002. Control of IRF-3 activation by 
phosphorylation. J Interferon Cytokine Res 22:73-76. 
66 
37. Fruman, D. A, R. E. Meyers, and L. C. Cantley. 1998. Phosphoinositide kinases. 
Annu Rev Biochem 67:481-507. 
38. Vanhaesebroeck, B., S. 1. Leevers, K. Ahmadi, 1. Timms, R. Katso, P. C. Driscoll, 
R. Woscholski, P. 1. Parker, and M. D. Waterfield. 2001. Synthesis and function 
of 3-phosphorylated inositol lipids. Annu Rev Biochem 70:535-602. 
39. Okkenhaug, K., and B. Vanhaesebroeck. 2001. New responsibilities for the PI3K 
regulatory subunit p85 alpha. Sci STKE 2001 :PE 1. 
40. Vanhaesebroeck, B., and M. D. Waterfield. 1999. Signaling by distinct classes of 
phosphoinositide 3-kinases. Exp Cell Res 253:239-254. 
41. Hazeki, K., K. Nigorikawa, and O. Hazeki. 2007. Role of phosphoinositide 3-
kinase in innate immunity. BioI Pharm Bull 30:1617-1623. 
42. Deane, J. A., and D. A Fruman. 2004. Phosphoinositide 3-kinase: diverse roles in 
immune cell activation. Annu Rev ImmunoI22:563-598. 
43. Cross, D. A, D. R. Alessi, P. Cohen, M. Andjelkovich, and B. A Hemmings. 
1995. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein 
kinase B. Nature 378:785-789. 
44. Frame, S., and P. Cohen. 2001. GSK3 takes centre stage more than 20 years after 
its discovery. Biochem J 359: 1-16. 
45. Jope, R. S., and G. V. Johnson. 2004. The glamour and gloom of glycogen 
synthase kinase-3. Trends Biochem Sci 29:95-102. 
46. Woodgett, 1. R. 2005. Recent advances in the protein kinase B signaling pathway. 
Curr Opin Cell BioI 17:150-157. 
47. Doble, B. W., and 1. R. Woodgett. 2003. GSK-3: tricks of the trade for a multi-
tasking kinase. J Cell Sci 116: 1175-1186. 
48. Hoeflich, K. P., 1. Luo, E. A Rubie, M. S. Tsao, o. Jin, and 1. R. Woodgett. 2000. 
Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB 
activation. Nature 406:86-90. 
49. Frame, S., P. Cohen, and R. M. Biondi. 2001. A common phosphate binding site 
explains the unique substrate specificity of GSK3 and its inactivation by 
phosphorylation. Mol Cell 7:1321-1327. 
50. Cohen, P., and S. Frame. 2001. The renaissance of GSK3. Nat Rev Mol Cell Bioi 
2:769-776. 
51. Kaur, S., S. Parmar, 1. Smith, E. Katsoulidis, Y. Li, A Sassano, B. Majchrzak, S. 
Uddin, M. S. Tallman, E. N. Fish, and L. C. Platanias. 2005. Role of protein 
67 
kinase C-delta (PKC-delta) in the generation of the effects of IFN-alpha In 
chronic myelogenous leukemia cells. Exp Hematol33:550-557. 
52. Kaur, S., A. Sassano, B. Dolniak, S. Joshi, B. Majchrzak-Kita, D. P. Baker, N. 
Hay, E. N. Fish, and L. C. Platanias. 2008. Role of the Akt pathway in mRNA 
translation of interferon-stimulated genes. Proc Natl Acad Sci USA 105 :4808-
4813. 
53. Lekmine, F., S. Uddin, A. Sassano, S. Parmar, S. M. Brachmann, B. Majchrzak, 
N. Sonenberg, N. Hay, E. N. Fish, and L. C. Platanias. 2003. Activation of the 
p70 S6 kinase and phosphorylation of the 4E-BP1 repressor ofmRNA translation 
by type I interferons. J Bio! Chem 278:27772-27780. 
54. Dajani, R., E. Fraser, S. M. Roe, N. Young, V. Good, T C. Dale, and L. H. Pearl. 
2001. Crystal structure of glycogen synthase kinase 3 beta: structural basis for 
phosphate-primed substrate specificity and autoinhibition. CellI 05 :721-732. 
55. ter Haar, E., 1. T CoIl, D. A. Austen, H. M. Hsiao, L. Swenson, and 1. Jain. 2001. 
Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat Struct 
Bio! 8:593-596. 
56. Roach, P. 1. 1991. Multisite and hierarchal protein phosphorylation. J Bio! Chem 
266:14139-14142. 
57. Fukao, T, M. Tanabe, Y. Terauchi, T Ota, S. Matsuda, T Asano, T Kadowaki, 
T Takeuchi, and S. Koyasu. 2002. PI3K-mediated negative feedback regulation 
ofIL-12 production in DCs. Nat Immuno!3:875-881. 
58. Guha, M., and N. Mackman. 2002. The phosphatidylinositol 3-kinase-Akt 
pathway limits lipopolysaccharide activation of signaling pathways and 
expression of inflammatory mediators in human monocytic cells. J BiD! Chem 
277:32124-32132. 
59. Martin, M., 1. Katz, S. N. Vogel, and S. M. Michalek. 2001. Differential induction 
of endotoxin tolerance by lipopolysaccharides derived from Porphyromonas 
gingival is and Escherichia coli. J Immuno!167:5278-5285. 
60. Martin, M., K. Rehani, R. S. Jope, and S. M. Michalek. 2005. Toll-like receptor-
mediated cytokine production is differentially regulated by glycogen synthase 
kinase 3. Nat Immuno!6:777-784. 
61. Pestka, S., C. D. Krause, and M. R. Walter. 2004. Interferons, interferon-like 
cytokines, and their receptors. Immuno! Rev 202:8-32. 
62. Berzsenyi, M. D., S. K. Roberts, and M. R. Beard. 2006. Genomics of hepatitis B 
and C infections: diagnostic and therapeutic applications of microarray profiling. 
Antivir Ther 11 :541-552. 
68 
63. Lam, S., S. Wang, and M. Gottesman. 2008. Interferon-beta 1 b for the treatment of 
multiple sclerosis. Expert Opin Drug Metab Toxicol4: 1111-1117. 
64. Maher, S. G., A. L. Romero-Weaver, A. 1. Scarzello, and A. M. Gamero. 2007. 
Interferon: cellular executioner or white knight? Curr Med Chem 14:1279-1289. 
65. Battaglia, A. M., and K. O. Hagmeyer. 2000. Combination therapy with interferon 
and ribavirin in the treatment of chronic hepatitis C infection. Ann Pharmacother 
34:487-494. 
66. Fritz, E., and H. Ludwig. 2000. Interferon-alpha treatment in multiple myeloma: 
meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 11 :1427-
1436. 
67. Kieseier, B. c., H. Wiendl, B. Hemmer, and H. P. Hartung. 2007. Treatment and 
treatment trials in multiple sclerosis. Curr Opin NeuroI20:286-293. 
68. Bogdan, C. 2000. The function of type I interferons in antimicrobial immunity. 
Curr Opin ImmunoI12:419-424. 
69. Baccala, R., K. Hoebe, D. H. Kono, B. Beutler, and A. N. Theofilopoulos. 2007. 
TLR-dependent and TLR-independent pathways of type I interferon induction in 
systemic autoimmunity. Nat Med 13:543-551. 
70. Kawai, T, and S. Akira. 2008. Toll-like receptor and RIG-I-like receptor 
signaling. Ann NY Acad Sci 1143: 1-20. 
71. Alexopoulou, L., A. C. Holt, R. Medzhitov, and R. A. Flavell. 200l. Recognition 
of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. 
Nature 413:732-738. 
72. Hemmi, H., T Kaisho, O. Takeuchi, S. Sato, H. Sanjo, K. Hoshino, T Horiuchi, 
H. Tomizawa, K. Takeda, and S. Akira. 2002. Small anti-viral compounds 
activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat 
Immunol3: 196-200. 
73. Jurk, M., E Heil, 1. Vollmer, C. Schetter, A. M. Krieg, H. Wagner, G. Lipford, 
and S. Bauer. 2002. Human TLR7 or TLR8 independently confer responsiveness 
to the antiviral compound R-848. Nat ImmunoI3:499. 
74. Heil, E, P. Ahmad-Nejad, H. Hemmi, H. Hochrein, E Ampenberger, T Gellert, 
H. Dietrich, G. Lipford, K. Takeda, S. Akira, H. Wagner, and S. Bauer. 2003. The 
Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong 
relationship within the TLR7, 8 and 9 subfamily. Eur J ImmunoI33:2987-2997. 
75. Diebold, S. S., T Kaisho, H. Hemmi, S. Akira, and C. Reis e Sousa. 2004. Innate 
antiviral responses by means of TLR7-mediated recognition of single-stranded 
RNA. Science 303: 1529-153l. 
69 
76. Heil, F., H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, S. Akira, G. 
Lipford, H. Wagner, and S. Bauer. 2004. Species-specific recognition of single-
stranded RNA via toll-like receptor 7 and 8. Science 303:1526-1529. 
77. Lund,1. M., L. Alexopoulou, A. Sato, M. Karow, N. C. Adams, N. W. Gale, A. 
Iwasaki, and R. A. Flavell. 2004. Recognition of single-stranded RNA viruses by 
Toll-like receptor 7. Proc Natl Acad Sci USA 101 :5598-5603. 
78. Bauer, S., C. 1. Kirschning, H. Hacker, V. Redecke, S. Hausmann, S. Akira, H. 
Wagner, and G. B. Lipford. 2001. Human TLR9 confers responsiveness to 
bacterial DNA via species-specific CpG motif recognition. Proc Nat! Acad Sci U 
SA 98:9237-9242. 
79. Hemmi, H., O. Takeuchi, T Kawai, T Kaisho, S. Sato, H. Sanjo, M. Matsumoto, 
K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Toll-like receptor 
recognizes bacterial DNA. Nature 408:740-745. 
80. Coccia, E. M., M. Severa, E. Giacomini, D. Monneron, M. E. Remoli, I. Julkunen, 
M. Cella, R. Lande, and G. Uze. 2004. Viral infection and Toll-like receptor 
agonists induce a differential expression of type I and lambda interferons in 
human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 
34:796-805. 
81. Kato, A., T Ogasawara, T Homma, H. Saito, and K. Matsumoto. 2004. 
Lipopolysaccharide-binding protein critically regulates lipopolysaccharide-
induced IFN-beta signaling pathway in human monocytes. J lmmunol 172:6185-
6194. 
82. To shchako v, v., B. W. Jones, P. Y. Perera, K. Thomas, M. 1. Cody, S. Zhang, B. 
R. Williams, 1. Major, T A. Hamilton, M. 1. Fenton, and S. N. Vogel. 2002. 
TLR4, but not TLR2, mediates IFN-beta-induced STATlalpha/beta-dependent 
gene expression in macrophages. Nat ImmunoI3:392-398. 
83. Le, V. T, M. Trilling, A. Zimmermann, and H. Hengel. 2008. Mouse 
cytomegalovirus inhibits beta interferon (IFN-beta) gene expression and controls 
activation pathways of the IFN-beta enhanceosome. J Gen Virol 89: 1131-114l. 
84. Eantuzzi, L., P. Eid, W. Malorni, G. Rainaldi, M. C. Gauzzi, S. Pellegrini, F. 
Belardelli, and S. Gessani. 1997. Post-translational up-regulation of the cell 
surface-associated alpha component of the human type I interferon receptor 
during differentiation of peripheral blood monocytes: role in the biological 
response to type I interferon. Eur J Immunol27: 1 075-1 081. 
85. Caraglia, M., G. Vitale, M. Marra, S. Del Prete, A. Lentini, A. Budillon, S. 
Beninati, and A. Abbruzzese. 2004. Translational and post-translational 
modifications of proteins as a new mechanism of action of alpha-interferon: 
review article. Amino Acids 26:409-417. 
70 
86. Maniatis, T., 1. V. Falvo, T. H. Kim, T. K. Kim, C. H. Lin, B. S. Parekh, and M. 
G. Wathelet. 1998. Structure and function of the interferon-beta enhanceosome. 
Cold Spring Harb Symp Quant Bioi 63:609-620. 
87. Kirchhoff, S., D. Wilhelm, P. Angel, and H. Hauser. 1999. NFkappaB activation 
is required for interferon regulatory factor-I-mediated interferon beta induction. 
Eur J Biochem 261:546-554. 
88. Honda, K., A. Takaoka, and T. Taniguchi. 2006. Type I interferon [corrected] 
gene induction by the interferon regulatory factor family of transcription factors. 
Immunity 25:349-360. 
89. Silverman, N., and T. Maniatis. 2001. NF-kappaB signaling pathways In 
mammalian and insect innate immunity. Genes Dev 15:2321-2342. 
90. Chu, W. M., D. Ostertag, Z. W. Li, L. Chang, Y. Chen, Y. Hu, B. Williams, 1. 
Perrault, and M. Karin. 1999. JNK2 and IKKbeta are required for activating the 
innate response to viral infection. Immunity 11:721-731. 
91. Panne, D., T. Maniatis, and S. C. Harrison. 2004. Crystal structure of ATF-2/c-
Jun and IRF-3 bound to the interferon-beta enhancer. EMBO J23:4384-4393. 
92. Kim, T. K., and T. Maniatis. 1997. The mechanism of transcriptional synergy of 
an in vitro assembled interferon-beta enhanceosome. Mol Cell 1: 119-129. 
93. Novick, D., B. Cohen, and M. Rubinstein. 1994. The human interferon alpha/beta 
receptor: characterization and molecular cloning. Cell 77:391-400. 
94. Stark, G. R., I. M. Kerr, B. R. Williams, R. H. Silverman, and R. D. Schreiber. 
1998. How cells respond to interferons. Annu Rev Biochem 67:227-264. 
95. Biron, C. A. 2001. Interferons alpha and beta as immune regulators--a new look. 
Immunity 14:661-664. 
96. Billiau, A. 2006. Anti-inflammatory properties of Type I interferons. Antiviral 
Res 71: 1 08-116. 
97. Darnell, 1. E., Jr., I. M. Kerr, and G. R. Stark. 1994. Jak-STAT pathways and 
transcriptional activation in response to IFNs and other extracellular signaling 
proteins. Science 264: 1415-1421. 
98. Moore, K. W., R. de Waal Malefyt, R. L. Coffman, and A. O'Garra. 2001. 
Interleukin-l0 and the interleukin-l 0 receptor. Annu Rev ImmunoI19:683-765. 
99. Aman, M. J., T. Tretter, I. Eisenbeis, G. Bug, T. Decker, W. E. Aulitzky, H. Tilg, 
C. Huber, and C. Peschel. 1996. Interferon-alpha stimulates production of 
interleukin-l0 in activated CD4+ T cells and monocytes. Blood 87:4731-4736. 
71 
100. Porrini, A. M., D. Gambi, and A. T. Reder. 1995. Interferon effects on 
interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in 
multiple sclerosis patients. J Neuroimmunol61 :27-34. 
101. Chang, E. Y, B. Guo, S. E. Doyle, and G. Cheng. 2007. Cutting edge: 
involvement of the type I IFN production and signaling pathway in 
lipopolysaccharide-induced IL-1 0 production. J ImmunoI178:6705-6709. 
102. Wang, X., M. Chen, K. P. Wandinger, G. Williams, and S. Dhib-Jalbut. 2000. 
IFN-beta-1 b inhibits IL-12 production in peripheral blood mononuclear cells in an 
IL-10-dependent mechanism: relevance to IFN-beta-1 b therapeutic effects in 
multiple sclerosis. J Immunol165 :548-557. 
103. McRae, B. 1., B. A. Beilfuss, and G. A. van Seventer. 2000. IFN-beta 
differentially regulates CD40-induced cytokine secretion by human dendritic 
cells. J ImmunoI164:23-28. 
104. Byrnes, A. A., X. Ma, P. Cuomo, K. Park, 1. Wahl, S. F. Wolf, H. Zhou, G. 
Trinchieri, and C. 1. Karp. 200 l. Type 1 interferons and IL-12: convergence and 
cross-regulation among mediators of cellular immunity. Eur J Immunol 31 :2026-
2034. 
105. Markowitz, C. E. 2007. Interferon-beta: mechanism of action and dosing issues. 
Neurology 68:S8-11. 
106. Takeda, K., and S. Akira. 2005. Toll-like receptors in innate immunity. In! 
ImmunoI17:1-14. 
107. Horng, T., G. M. Barton, R. A. Flavell, and R. Medzhitov. 2002. The adaptor 
molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 
420:329-333. 
108. Horng, T., G. M. Barton, and R. Medzhitov. 2001. TlRAp: an adapter molecule in 
the Toll signaling pathway. Nat ImmunoI2:835-841. 
109. Yamamoto, M., S. Sato, H. Hemmi, H. Sanjo, S. Uematsu, T. Kaisho, K. 
Hoshino, O. Takeuchi, M. Kobayashi, T. Fujita, K. Takeda, and S. Akira. 2002. 
Essential role for TlRAP in activation of the signalling cascade shared by TLR2 
and TLR4. Nature 420:324-329. 
110. Medzhitov, R., P. Preston-Hurlburt, E. Kopp, A. Stadlen, C. Chen, S. Ghosh, and 
C. A. Janeway, Jr. 1998. MyD88 is an adaptor protein in the hToll/lL-1 receptor 
family signaling pathways. Mol Cell 2:253-258. 
111. Martin, M., R. E. Schifferle, N. Cuesta, S. N. Vogel, J. Katz, and S. M. Michalek. 
2003. Role of the phosphatidylinositol 3 kinase-Akt pathway in the regulation of 
IL-10 and IL-12 by Porphyromonas gingivalis lipopolysaccharide. J Immunol 
171:717-725. 
72 
112. Hu, x., P. K. Paik, 1. Chen, A. Yarilina, L. Kockeritz, T T Lu, 1. R. Woodgett, 
and L. B. Ivashkiv. 2006. IFN-gamma suppresses IL-I0 production and 
synergizes with TLR2 by regulating GSK3 and CREBI AP-l proteins. Immunity 
24:563-574. 
113. Rodionova, E., M. Conzelmann, E. Maraskovsky, M. Hess, M. Kirsch, T Giese, 
A. D. Ho, M. Zoller, P. Dreger, and T Luft. 2007. GSK-3 mediates differentiation 
and activation of pro inflammatory dendritic cells. Blood 109: 1584-1592. 
114. Cross, D. A., A. A. Culbert, K. A. Chalmers, L. Facci, S. D. Skaper, and A. D. 
Reith. 200 l. Selective small-molecule inhibitors of glycogen synthase kinase-3 
activity protect primary neurones from death. J Neurochem 77:94-102. 
115. Stambolic, V, and 1. R. Woodgett. 1994. Mitogen inactivation of glycogen 
synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J 303 
(Pt 3):701-704. 
116. Panne, D., T Maniatis, and S. C. Harrison. 2007. An atomic model of the 
interferon-beta enhanceosome. Cell 129: 1111-1123. 
117. Morton, S., R. 1. Davis, A. McLaren, and P. Cohen. 2003. A reinvestigation of the 
multi site phosphorylation of the transcription factor c-Jun. EMBO J 22:3876-
3886. 
118. Wei, W., 1. Jin, S. Schlisio, 1. W. Harper, and W. G. Kaelin, lr. 2005. The v-lun 
point mutation allows c-Jun to escape GSK3-dependent recognition and 
destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8:25-33. 
119. Smeal, T, B. Binetruy, D. A. Mercola, M. Birrer, and M. Karin. 1991. Oncogenic 
and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on 
serines 63 and 73. Nature 354:494-496. 
120. Kawai, T, O. Adachi, T Ogawa, K. Takeda, and S. Akira. 1999. 
Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11: 115-122. 
121. Takahasi, K., T Fujita, and F. Inagaki. 2004. [Three dimensional structure of 
IRF-3 and its implication in signal transduction]. Tanpakushitsu Kakusan Koso 
49:1280-1287. 
122. Takahasi, K., N. N. Suzuki, M. Horiuchi, M. Mori, W. Suhara, Y. Okabe, Y. 
Fukuhara, H. Terasawa, S. Akira, T Fujita, and F. Inagaki. 2003. X-ray crystal 
structure oflRF -3 and its functional implications. Nat Struct BioI 10:922-927. 
123. Stockinger, S., B. Reutterer, B. Schaljo, C. Schellack, S. Brunner, T Materna, M. 
Yamamoto, S. Akira, T Taniguchi, P. 1. Murray, M. Muller, and T Decker. 2004. 
IFN regulatory factor 3-dependent induction of type I IFNs by intracellular 
bacteria is mediated by a TLR- and Nod2-independent mechanism. J Immunol 
173:7416-7425. 
73 
124. Santini, S. M., T. Di Pucchio, C. Lapenta, S. Parlato, M. Logozzi, and F. 
Belardelli. 2002. The natural alliance between type I interferon and dendritic cells 
and its role in linking innate and adaptive immunity. J Interferon Cytokine Res 
22: 1 071-1 080. 
125. Goh, K. C., S. 1. Haque, and B. R. Williams. 1999. p38 MAP kinase is required 
for STAT 1 serine phosphorylation and transcriptional activation induced by 
interferons. EMBO J 18:5601-5608. 
126. Uddin, S., E. N. Fish, D. A. Sher, C. Gardziola, M. F. White, and L. C. Platanias. 
1997. Activation of the phosphatidylinositol 3-kinase serine kinase by IFN-alpha. 
J ImmunoI158:2390-2397. 
127. Polumuri, S. K., V. Y. Toshchakov, and S. N. Vogel. 2007. Role of 
phosphatidylinositol-3 kinase in transcriptional regulation of TLR-induced IL-12 
and IL-I0 by Fc gamma receptor ligation in murine macrophages. J Immunol 
179:236-246. 
128. Jope, R. S., C. J. Yuskaitis, and E. Beurel. 2007. Glycogen synthase kinase-3 
(GSK3): inflammation, diseases, and therapeutics. Neurochem Res 32:577-595. 
129. Markou, T., T. E. Culling ford, A. Giraldo, S. C. Weiss, A. Alsafi, S. 1. Fuller, A. 
Clerk, and P. H. Sugden. 2008. Glycogen synthase kinases 3alpha and 3beta in 
cardiac myocytes: regulation and consequences of their inhibition. Cell Signal 
20:206-218. 
130. Lee, T. P., S. 1. Leu, 1. C. Huang, Y. C. Song, R. S. Jhou, S. 1. Tang, and K. H. 
Sun. 2008. Anti-ribosomal phosphoprotein autoantibody triggers interleukin-l0 
overproduction via phosphatidylinositol 3-kinase-dependent signalling pathways 
in lipopolysaccharide-activated macrophages. Immunology. 
131. Uddin, S., B. Majchrzak, 1. Woodson, P. Arunkumar, Y. Alsayed, R. Pine, P. R. 
Young, E. N. Fish, and L. C. Platanias. 1999. Activation of the p38 mitogen-
activated protein kinase by type I interferons. J Bioi Chern 274:30127-30131. 
132. Uddin, S., B. Majchrzak, P. C. Wang, S. Modi, M. K. Khan, E. N. Fish, and L. C. 
Platanias. 2000. Interferon-dependent activation of the serine kinase PI 3'-kinase 
requires engagement of the IRS pathway but not the Stat pathway. Biochem 
Biophys Res Commun 270:158-162. 
133. Livak, K. 1., and T. D. Schmittgen. 2001. Analysis of relative gene expression 
data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. 
Methods 25 :402-408. 
134. Welsh, G. I., C. M. Miller, A. 1. Loughlin, N. T. Price, and C. G. Proud. 1998. 
Regulation of eukaryotic initiation factor eIF2B: glycogen synthase kinase-3 
phosphorylates a conserved serine which undergoes dephosphorylation in 
response to insulin. FEBS Lett 421: 125-130. 
74 
135. Fiol, C. 1., A. M. Mahrenholz, Y. Wang, R. W. Roeske, and P. 1. Roach. 1987. 
Formation of protein kinase recognition sites by covalent modification of the 
substrate. Molecular mechanism for the synergistic action of casein kinase II and 
glycogen synthase kinase 3. J Bioi Chem 262:14042-14048. 
136. Yang, C. H., A. Murti, S. R. Pfeffer, M. Fan, Z. Du, and L. M. Pfeffer. 2008. The 
role of TRAF2 binding to the type I interferon receptor in alternative NF kappaB 
activation and antiviral response. J Bioi Chem 283:14309-14316. 
l37. Nagai, T., O. Devergne, T. F. Mueller, D. L. Perkins, 1. M. van Seventer, and G. 
A. van Seventer. 2003. Timing of IFN-beta exposure during human dendritic cell 
maturation and naive Th cell stimulation has contrasting effects on Thl subset 
generation: a role for IFN-beta-mediated regulation ofIL-12 family cytokines and 
IL-18 in naive Th cell differentiation. J Immunol171 :5233-5243. 
l38. Lande, R., E. Giacomini, T. Grassi, M. E. Remoli, E. lona, M. Miettinen, I. 
Julkunen, and E. M. Coccia. 2003. IFN-alpha beta released by Mycobacterium 
tuberculosis-infected human dendritic cells induces the expression of CXCL 1 0: 
selective recruitment ofNK and activated T cells. J Immunol170: 1174-1182. 
139. Heystek, H. c., B. den Drijver, M. L. Kapsenberg, R. A. van Lier, and E. C. de 
Jong. 2003. Type I IFNs differentially modulate IL-12p70 production by human 
dendritic cells depending on the maturation status of the cells and counteract IFN-
gamma-mediated signaling. Clin Immunol1 07: 170-177. 
140. Rep, M. H., H. M. Schrijver, T. van Lopik, R. Q. Hintzen, M. T. Roos, H. 1. Ader, 
C. H. Polman, and R. A. van Lier. 1999. Interferon (IFN)-beta treatment enhances 
CD95 and interleukin 10 expression but reduces interferon-gamma producing T 
cells in MS patients. J NeuroimmunoI96:92-1 00. 
141. Wegenka, U. M., N. Dikopoulos, 1. Reimann, G. Adler, and C. Wahl. 2007. The 
murine liver is a potential target organ for IL-19, IL-20 and IL-24: Type I 
Interferons and LPS regulate the expression ofIL-20R2. J Hepatol 46:257-265. 
142. Dikopoulos, N., A. Bertoletti, A. Kroger, H. Hauser, R. Schirmbeck, and 1. 
Reimann. 2005. Type I IFN negatively regulates CD8+ T cell responses through 
IL-lO-producing CD4+ T regulatory 1 cells. J ImmunoI174:99-109. 
143. Florquin, S., Z. Amraoui, D. Abramowicz, and M. Goldman. 1994. Systemic 
release and protective role of IL-10 in staphylococcal enterotoxin B-induced 
shock in mice. J ImmunoI153:2618-2623. 
144. Jansen, P. M., T. C. van der Pouw Kraan, I. W. de long, G. van Mierlo, 1. 
Wijdenes, A. A. Chang, L. A. Aarden, F. B. Taylor, Jr., and C. E. Hack. 1996. 
Release of interleukin-12 in experimental Escherichia coli septic shock in 
baboons: relation to plasma levels of interleukin-l 0 and interferon-gamma. Blood 
87:5144-5151. 
75 
145. Gerard, c., C. Bruyns, A Marchant, D. Abramowicz, P. Vandenabeele, A 
Delvaux, W. Fiers, M. Goldman, and T. Velu. 1993. Interleukin 10 reduces the 
release of tumor necrosis factor and prevents lethality in experimental 
endotoxemia. J Exp Med 177:547-550. 
146. Iwasaki, A, and R. Medzhitov. 2004. Toll-like receptor control of the adaptive 
immune responses. Nat Immunol 5:987-995. 
147. Mantovani, A, C. Garlanda, M. Locati, T. V. Rodriguez, S. G. Feo, B. Savino, 
and A Vecchio 2007. Regulatory pathways in inflammation. Autoimmun Rev 7:8-
11. 
148. Guerau-de-Arellano, M., and B. T. Huber. 2005. Chemokines and Toll-like 
receptors in Lyme disease pathogenesis. Trends Mol Med 11: 114-120. 
149. Ulevitch, R. 1., and P. S. Tobias. 1995. Receptor-dependent mechanisms of cell 
stimulation by bacterial endotoxin. Annu Rev Immunol 13 :437 -457. 
150. Asadullah, K., W. Sterry, and H. D. Volk. 2003. Interleukin-1 0 therapy--review of 
a new approach. Pharmacol Rev 55:241-269. 
151. Schaefer, A., C. Unterberger, M. Frankenberger, M. Lohrum, K. 1. Staples, T. 
Werner, H. Stunnenberg, and L. Ziegler-Heitbrock. 2009. Mechanism of 
Interferon-gamma mediated down-regulation of Interleukin-1 0 gene expression. 
Mol ImmunoI46:1351-1359. 
152. Mosser, D. M., and X. Zhang. 2008. Interleukin-10: new perspectives on an old 
cytokine. Immunol Rev 226:205-218. 
153. Lambert, S. L., and O. M. Martinez. 2007. Latent membrane protein 1 of EBV 
activates phosphatidylinositol 3-kinase to induce production of IL-1 O. J Immunol 
179:8225-8234. 
154. Garcia, C. A, M. R. Benakanakere, P. Alard, M. M. Kosiewicz, D. F. Kinane, and 
M. Martin. 2008. Antigenic experience dictates functional role of glycogen 
synthase kinase-3 in human CD4+ T cell responses. J Immuno1181:8363-8371. 
76 
CURRICULUM VITAE 
Name: Huizhi Wang 
Place of Birth: Luo Yang, Henan Province, China 
Date of Birth: April 23, 1975 
Present address 
Huizhi Wang 
501 South Preston Street, School of Dentistry, Room 211 B 
University of Louisville, Louisville, K Y, 40202 
Tel: (502)-852-1589 
E-mail: hh~.{ql)gQJ@gyyi.~(;.IS2 ~li~vjU~,9"tU or Ij-'1QyybJJi?'hI@Y~JhQQ,_~_QJ1L<:1l 
Education 
Sep,2005~ present, 
Sep, 1998~Jul,200 1 
Sep, 1993~Jul, 1998 
Employment 
Ph.D graduate student, 
Department of Microbiology and Immunology, 
Oral Health and Systemic Disease Research Group, 
University of Louisville, 
Louisville, KY 40202, USA. 
Department of Molecular pathogeny and microbiology, 
Zhengzhouuniversity, China 
Medicine Master Degree was awarded on Jul, 2001 
Department of Preventive medicine, 
Henan medical university, China, 
Medicine Bachelor degree Awarded on July 1998. 
Sep,2004~ Aug,2005 Technician support 
Invitrogen Corporation (Carlsbad, CA, U.S.A), Shanghai 
Aug, 2001-Sep, 2004, Research Associate 
State Key Laboratory of Molecular Biology, 
Institute of Biochemistry and Cell Biology, 
77 
Shanghai Institutes for Biological Sciences, 
Chinese Academy of Sciences, Shanghai, China 
Honors and Awards 
Aug, 2001, The "First-class medical and sanitary science award of Henan province" for 
my dissertation 
Jun, 2000, The "Federal medical scholarship and a medal for the top 10" 
Oct, 1999, The "First Class Medical knowledge Service for community" 
Mar, 1998, Henan medical university First-class scholarship. 
Research Expericences: 
1. Research in Ph.D. Graduate Study: 
Identifying and characterizing the critical components of cell signaling pathways 
regulating host inflammatory responses, specifically, exploring the functional role of 
glycogen synthase kinase 3 (GSK3), the downstream constitutive activate 
serine/threonine kinase of PI3K pathway, in the innate immune responses and evaluating 
its therapeutic efficacy that could attenuate the inflammation disease in vivo. Our 
laboratory has identified GSK3~ as a central regulator of the inflammatory process by its 
ability to differentially regulate the levels of pro- and anti-inflammatory cytokines upon 
TLR activation. My work focuses on the regulatory role of GSK3-~ to the TLR4-induced 
type I interferon as well as the interferon beta induced prototypical immunosuppressive 
cytokine, IL-l o. Given the pivotal role of GSK3 ~ in the TLR induced inflammatory 
immune response, I am also interested in the crosstalk of GSK3-CREB pathway to other 
classical inflammation related pathway like mTORCl and beta-catenin pathways. From I 
joined in this lab to now, I have finished two projects and the third one is on going. 
(1). IFN-~ production induced by TLR4 is negatively regulated by GSK3-p 
(2). Functional role of GSK3~ in IFN-~ induced IL-lO production 
78 
(3). GSK3~ regulates the mTOR-mediated inflammatory response in TLR-stimulated 
innate immune cells 
2. As a research assocaite in Institute of Biochemistry and Cell Biology, Shanghai, I am 
mainly responsible for and have finished three projects: 
(1). The application ofNanocrystal Quantum Dots in the cell biology and diagnosis. 
Given several advantages of Quantum Dots including higher quantum yield, exceptional 
photo-stability, a narrow, tunable, and symmetric emission spectrum, we determine 
whether it can be used as a novel fluorescent probe to labeling some cell molecules in 
vitro and in vivo. By using Quantum Dots with emission wavelength 605 (QD605) to 
label tumor marker CAl2S, we found the exceptional photo-property ofQDs to label the 
bio-molecule in various specimens which suggested QDs might be used extensively in 
bio-detecting and clinical diagnosis as a novel fluorescent probe. 
(2). Improvement the technique of protein-microarray and development the secondary 
generation of bio-microarry including microRNA-array, high thought DNA-array. 
Investigating the application of Quantum dots in the multiple channels of SPR platform 
and subsequently enhances the signal/noise ratio and expand its application in the cell 
biology. 
(3). Use fluorescence resonance energy transfer (FRET) and hydrostatic pressure to 
explore the principle of protein folding/unfolding in some disease conditions like early 
phase of Alzheimer. 
3. As a biology master candidate, from Ju1.l998~2001, , finishing the project named 
"cloning and expression of 31kDa structure gene in pre-cyst trichinella" which provided 
me much experience on various basic molecular biology techniques such as RNA 
extraction, real time-PCR, cloning and expression, Mutagenesis, Cell culture, 
79 
Immunochemistry and ISH, Western-blot and Protein purification. Additionally, other 
collaboration projects provide me many chances to familiar with many techniques on 
mice work. 
PUBLICATIONS 
1. Wang H, Garcia CA, Alard P, Mitchell T, Kinane DF, Martin M. GSK3B 
regulates the mTOR-mediated inflammatory response in TLR-stimulated innate 
immune cells (in prepration) 
2. Garcia CA, Wang H, Benakanakere, M.R., Kinane DF, Martin M. Inhibition of 
GSK3-b in human CD4+ memory T cells promotes IL-I0 production upon IL12 
stimulation. (Submitted) 
3. Wang H, Benakanakere, M.R., Garcia CA, Kinane DF, Martin M. Interferon beta 
(lFN -B)-induced IL-10 production in human Monocyte-derived Dendritic cells 
was negatively regulated by Glycogen Synthase Kinase 3-beta (GSK3-B) 
(Submitted) 
4. Wang H, Garcia CA, Rehani K, Cekic C, Alard P, Kinane DF, Alard P, Mitchell 
T, Martin M. IFN-beta production by TLR4-stimulated innate immune cells is 
negatively regulated by GSK3-beta. J Immunol. 2008 Nov 15; 181 (1 0):6797-802. 
5. Wang H, Rehani K, Garcia CA, Kinane DF, Martin M. Toll-like receptor-
mediated production of IL-1Ra is negatively regulated by GSK3 via the MAPK 
ERK1I2, J Immunol, 2009,Jan 1;182(1):547-53 (Co-first author) 
6. Rehani K, Scott DA, Renaud D, Hamza H, Williams LR, Wang H, Martin M. 
Cotinine-induced convergence of the cholinergic and PI3 kinase-dependent anti-
inflammatory pathways in innate immune cells. Biochim Biophys Acta. 2008 
Mar; 1783(3):375-82. 
7. Wang H, Liang RQ, Wang HY, Ruan KC. Detection of tumor marker CA125 in 
ovarian carcinoma using quantum dots. Acta Biochim Biophys Sin, 2004 Oct; 36 
(10): 681-6 
8. Wang H, Wang ZQ, Cui J. Application research of recombinant antigen on 
immune diagnoses and immune prophylaxis of Trichinosis. Chinese Journal of 
Zoonoses,2002, 18( 6) :96-98 
80 
9. Cui J, Wang ZQ, Wang H, Zhao GQ, Zhang HW etc. Cloning and Expression of 
the Antigen Structural Gene TspE 1 from Pre-encysted Larvae of Trichinella 
spiralis. Chin J Parasitol Parasit Dis, 2002,20(5):278-280 
10. Cui J, Zhao GQ, Wang H, Zhang HW etc. Cloning and sequencing of the gene 
encoding a 31 kDa antigen of Trichinella spiralis pre-encysted larvae. Chinese 
Journal of Zoonoses, 2002, 18( 5):37 -41 
11. Cui J, Wang ZQ, Wang H, etc. Molecular cloning and genetic polymorphism 
analysis of TspE1 gene of Henan isolates of Trichinella spiralis. Journal of 
Zhengzhou university (Medical Sciences), 2002, 37(3):295-300 
12. Cui J, Wang ZQ, Zhang RG, Wang H,etc. Research of Trichinosis on 
epidemiology, clinic medicine, serumology and molecular biology. Henan 
Medicine Research, 2002,11(1):347-348 
81 
